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Nitric oxide (NO) is an endogenously produced bioregulatory agent that also is toxic.  
Disturbances in NO production and regulation are known to cause central nervous system 
disorders and asthma among many other diseases.  Iron nitrosyl complexes help to balance the 
beneficial effects of NO against its potentially fatal effects. This document reviews the literature 
devoted to structural and chemical characteristics of iron nitrosyl porphyrin complexes, 
bimetallic iron containing nitrosyl complexes, dinitrosyl complexes, iron nitrosyl cluster 
complexes, and non-heme nitrosyl complexes prepared between 1992  and 2002.  
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 1. IRON NITROSYL COMPLEXES  
1.1. INTRODUCTION 
     Nitric oxide (NO) is an endogenously produced bioregulatory agent that also is toxic.  
Being a small, uncharged molecule, NO can diffuse freely across cell membranes.  However, 
because of its multiple and sometimes paradoxical roles as a neurotransmitter, autacoid, 
constitutive mediator, inducible mediator, cytoprotective molecule, and as a cytotoxic molecule, 
nitric oxide's release and action must be well regulated. Disturbances in NO regulatory pathways 
are known to cause central nervous system disorders, diabetes mellitus, asthma, gastrointestinal 
disorders, and atherosclerosis.1  In particular, the pathophysiological effects of vascular nitric 
oxide are well known and have been reviewed.2  Nitric oxide release is also related to 
hypotension characteristic of septic shock that is induced by group B streptococcus, the leading 
cause of sepsis in neonates.3 Yet, nitric oxide has been incorporated into non-steroidal and anti-
inflammatory drugs (NSAIDs) to inhibit gastrointestinal side effects.4  This subject has also been 
reviewed.  Figure 1.15 summarizes many of the other physiological benefits and pathological 
effects elicited by NO.    As will be discussed in this document, iron nitrosyl complexes play a 
major role in balancing the beneficial effects of NO against its potentially fatal effects. 
Given the myriad bioregulatory and pathophysiological roles of NO, most pharmaceutical 
companies have devoted some of their research efforts to the discovery of NO based therapeutic 
drugs.1  Therefore, elucidation of the mechanisms by which NO is produced and regulated in the 
body is a goal which has been pursued by chemists, biochemists, and biologists. Because 
scientists initially studied nitric oxide within their respective fields, nitric oxide reviews have 
emphasized either chemistry6-15 or biology2,4,16-23 with nomenclature specific to each.24   More 
recent reviews have been written from a combined perspective.1  
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The divergent routes scientists have taken to understand nitric oxide’s origin and function 
have lead to the common conclusion that heme and non-heme iron nitrosyl complexes are 
involved in many aspects of nitric oxide regulation, transport, pathophysiology, and function.  
This review is limited to the iron nitrosyl complexes that have been prepared between 1992 
(when Richter-Addo and Legzdins published their book, Metal Nitrosyls.25) and 2002.  
Physiological roles, synthetic methods and chemical characteristics of iron nitrosyls are 
discussed. 
 
Figure 1.1   −  Physiological and Pathophysiological Roles of Nitric Oxide 
(Reproduced from Cell, 78, 919-925, “NO at Work”, H. W. Schmidt and Walter Ulrich, Copyright 1994, with 
permission from Elsevier. 4)  
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 1.2. NITRIC OXIDE SYNTHASE 
Nitric oxide is produced in the body by nitric oxide synthase (NOS).  The subject has been 
reviewed.5,16,18-20,22  NOS has several isoforms (distinct forms).26,27  Appendix A describes the 
different isoforms, their structural features, characterization, and activation. This section 
describes the proposed mechanism by which nitric oxide synthase oxidizes N-hydroxyl-L-
arginine to citrulline to produce NO. 
NOS enzymes have a heme domain that consumes five electrons to produce nitric oxide 
directly from the guanidine nitrogen of L-arginine.  The mechanism of electron transfer has been 
proposed to be similar to that of cytochrome p-450 in which NADPH (nicotinamide adenine 
dinucleotide phosphate) reduces FAD (flavin adenine dinucleotide) which in turn reduces FMN 
(flavin mononucleotide; for structure see Appendix A). FMN ultimately transfers electrons to 
ferric heme to promote the interaction with molecular oxygen shown in Figure 1.2.26  In the first 
step, L-arginine binds close to the ferric heme.  As an electron is transferred to the heme, oxygen 
binds to the iron center.  After a second electron from NADPH promotes cleavage of the oxygen-
oxygen bond, the remaining oxygen atom inserts into a terminal guanidino N-H bond to form N-
hydroxyl arginine as an enzyme bound intermediate.  In the second step, as another electron is 
transferred from NADPH to ferric heme, another oxygen molecule bonds with the iron center.  
The resulting ferrous oxyheme may oxidize bound N-hydroxyl arginine to form a peroxide iron 
species.  The peroxide iron species may then attack the guanidine carbon to yield citrulline, NO, 
H2O and ferric heme. There is evidence for heme participation in both oxidation steps from 
carbon monoxide inhibition studies28,29  and from optical difference binding studies.29,30    
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Figure 1.2   − Nitric Oxide Synthesis  
(Reprinted from Nitric Oxide Principles and Actions, “The Intracellular Reactions of Nitric oxide in the Immune 
System and Its Enzymatic Synthesis”, Jack Lancaster, Jr. and Dennis J. Stuehr, p. 154, Copyright 1996, with 
permission from Elsevier.) 
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 1.3. BIOLOGICAL ROLES OF IRON NITROSYL COMPLEXES 
From the discussion of nitric oxide synthesis it is clear that iron heme complexes are important in 
NO synthesis.  Iron heme complexes, as well as many other iron complexes, have a propensity to 
bind with nitric oxide to form iron nitrosyl complexes. In general, a physiological response is 
elicited upon formation of an iron nitrosyl complex in a target heme protein. Non-heme and 
cluster31 iron nitrosyl complexes are also involved in biological chemistry.  
Crane32 and co-workers have determined the structure of an NOS heme protein from 
Bacillus subtillus.  While the structure suggests that this NOS produces NO from L-arginine and 
NHA (N-hydroxy-L-Arginine) in a pterin dependent manner (Appendix A), the regulation and 
purpose of its production may be very different from that in mammals.  Human pathogens such 
as Staphylococcus aureus and Bacillus anthracis (Anthrax) have proteins very similar to Bacillus 
subtillus.  If the Staphylococcus aureus and Bacillus anthracis NOS proteins are found to be 
crucial for viability or pathogenicity, much that is known about NOS regulation in mammalian 
cells can be applied to fight these pathogens in humans. As noted by Crane and co-workers, 
structural differences in the heme pocket, pterin site, and substrate access channels of the 
Bacillus subtillus NOS could allow inhibitors to discriminate between bacterial and mammalian 
NOS proteins.   
Nitric oxide forms heme and sulfur containing iron nitrosyl complexes with targets in 
murine (mouse) tumor cells.33  EPR (electron paramagnetic resonance) signals of nitrosylated 
heme and non-heme iron containing dinitrosyls were also observed from tissues after rat heart 
allograft rejection.34  The most notable target for NO in the natural function of cells is guanylate 
cyclase, another iron heme involved in vasodilation.  Evidence for a five-coordinated 
[FeII(heme)(NO)] complex that catalyzes formation of the muscle relaxer, cGMP, has been 
detected by Raman spectroscopy.5,20 
5 
 NO binds to reduced cobalamin as a CoII(NO) complex.35-37  There have been numerous 
claims and counterclaims about NO coordination with aquacobalamin (CoIII).  Early reports 
claimed NO would not coordinate.38 Later, evidence suggested that aquacobalamin does bind 
NO.39-45  But recent studies of Van Eldik show that vitamin B12 and cobalamin coordinate with 
NO2− impurities rather than NO itself. The CoII form of cobalamin reacts much faster with NO• 
than with NO2−, 46 a feature also observed with iron hemes.47  
The action of NO on suppressing or promoting cellular redox events is quite 
controversial.  There are reports that NO complexes sacrificially reduce cytotoxicity in cells by 
removing organic peroxides, H2O2, and high valent iron species.48,49  Another mode of control 
upon cellular redox events is through coordination to metal sites in a fashion that prevents 
Fenton-type catalysis.50-52  A discussion of this work is provided in Appendix B for those who 
wish additional details.   
A major aspect of NO storage is illustrated by the discovery that NO is transported in the 
bloodstream as an S-nitrosylated thiol, predominantly with glutathione (GSH) as the carrier, but 
also directly attached to a cysteine functionality of hemoglobin, and not at the heme site.53 
Details of these types of NO carriers as well as of other physiological implications of NO appear 
in Appendix B.  These examples show that metal nitrosyl complexes represent both active 
molecules and inhibited molecules, in the diverse chemistry that has been, and continues to be, 
uncovered for physiological NO.   
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 1.4. COMMON IRON NITROSYL SYNTHETIC METHODS 
Since iron nitrosyl complexes and iron complexes that bind nitric oxide have important 
physiological and industrial applications, several synthetic methods have been developed. Some 
of the common methods for preparing transition metal nitrosyl complexes are summarized in this 
section.  These representative cases serve as examples of synthetic strategies that have been used 
to prepare the iron nitrosyl complexes that appear in the main body of this review.  In the later 
sections, attention will be given to the structure and reactivity, rather than to the synthesis as long 
as one of the standard preparative routes has been followed.  Extensive collections of preparatory 
methods have been given by Mingos and Sherman,8 Richter-Addo et al.,17 Greenwood and 
Earnshaw,54 and Caulton55,56 more recently in reviews by Legzdins et al.,9 and Ford and 
Lorkovic.6 
1.4.1. NITROSYLATION BY NO+ DONORS  
Ligand displacement by NO+ delivery agents such as [NO+]BF4 is the most common method, 
after addition of NO gas, to displace a solvent molecule. Treating metal carbonyl complexes with 
(NO)PF6 or (NO)BF4, allows for substitution of CO by the isoelectronic NO+ ligand. For 
example, Simpson and King prepared [(η5-C5H5)Fe(P{OMe}3)(NO)(I)]BF4 from its CO 
analogue57,58 and (NO)BF4.59  X-ray and 31P NMR evidence showed that the better π-accepting 
ability of the cationic NO ligand reduces the degree of iron to phosphorous back-donation such 
that [(η5-C5H5)Fe(P{OMe}3)(NO)(I)]BF4    exhibits a longer Fe-P bond and shorter P-OCH3 
bonds than its CO precursor.   
PF6− and BF4− salts of NO+ also serve as a source of NO+ for the direct addition to 
coordinatively unsaturated transition metal complexes.  Sellman and co-workers used this direct 
addition pathway to prepare a series of 18- and 19-electron iron nitrosyls of the pentadentate 
7 
 ligand, 2,6-bis(2-mercaptophenylthiomethyl)pyridine2− as presented in Figure 1.3.60  Reaction 
path a of Scheme 1.2 illustrates the direct addition reaction, while path b is another example of 
the CO displacement route using NO+ as the entering ligand.  Both routes form the same nitrosyl 
product, but path b has a lower yield and requires additional purification from the precursor 
complex. 
1.4.2. DIRECT ADDITION OF NO GAS 
While direct addition of nitric oxide gas is a convenient method of preparing transition metal 
nitrosyl complexes, nitric oxide gas degrades to N2O and NO2 under pressure and must be  
purified prior to use under an inert atmosphere.46,61,62 
Reaction path c in Figure 1.3 of Sellman et al.60 illustrates a reaction in which a 
coordinatively unsaturated complex is exposed to NO gas.  Stoichiometric addition yields the 
mono nitrosyl via path c.  But excess NO affords a dinitrosyl product (path f).  Two iron nitrosyls 
that differ by one electron (central complex shown in Figure 1.3) were prepared by this method.  
These two complexes have been compared by X-ray crystallography, DFT calculations, cyclic 
voltammetry and IR methods which reveal that the site of the extra electron is largely localized 
on the NO ligand and an FeII center in both species.60 
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Figure 1.3   − Nitrosylation by NO Donors and Direct Addition of NO Gas 
a) CH2Cl2, NOBF4, 25 ºC; b) CH2Cl2, NOBF4, 0 ºC;  c) CH2Cl2, 1 equiv of NO(g), 25 ºC; d) CH2Cl2, N2H4, NH3, 
NaNH2, NEt4N3, BuNH2, MeOH, or DMF, 25 ºC; e) CH2Cl2, [Cp2Fe]PF6, 78 ºC; f) CH2Cl2, excess NO (g), 25 ºC; g) 
CH2Cl2, excess NO (g), 25 ºC; h) CH2Cl2, excess NO (g), 25 ºC.  (Reprinted from Chem. Eur. J., 2001, 7, 1874, 
“Synthesis, Reactivity, and Structure of Strictly Homologous 18 and 19 Valence Electron Iron Nitrosyl Complexes”, 
Dieter Sellmann, Nicole Blum, Frank W. Heinemann, and Bernd A. Hess, Copyright 2001, with permission from 
Wiley-VHC. 60)  
 
1.4.3. SODIUM NITRITE AS AN NO+ SOURCE  
NO+ may be generated from NaNO2 and a mineral acid in organic or aqueous media.63  
Bhattacharya and co-workers prepared two thiolato-bridged Roussin’s esters, 
[(NO)2Fe(BM)2Fe(NO)2]  (BM = benzyl mercapto anion) and [(NO)2Fe(ME)Fe(NO)2]  (ME = 
2–mercaptoethanoate anion).  They also prepared a monomeric, paramagnetic dinitrosyl, 
[Fe(NO)2(ABT)] (ABT = 2-aminobenzylthiolato anion) which is reported to be stable under 
aerobic conditions in aqueous solution.  All three species were characterized by IR, EPR and 
electrochemical methods.64 
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 1.4.4. HYDROXYLAMINE AS AN NO SOURCE  
Reductive nitrosylation, in which a coordinated hydroxylamine (NH2OH) is oxidized to NO, at 
the expense of an additional molecule of NH2OH being reduced to NH3, is a convenient way to 
introduce coordinated NO, particularly 15NO, via 15NH2OH. Ryan and co-workers have utilized 
this route to prepare various nitrosyl porphyrin complexes of formulation Fe(P)(NO) (P = 
tetraphenylporphyrin (TPP), octaethyl porphyrin (OEP), or tetrachlorin (TPC)) in quantitative 
yields in a 1:1 methanol/chloroform solution at room temperature. The desired product 
precipitates at room temperature.65  The protoporphyrin IX dimethyl ester complex, 
Fe(PPDME)(NO) was obtained from a 4:1 methanol/chloroform solution.  Co, Mn, and Cr 
porphyrins were also prepared by this method. 
1.4.5. NITROSAMIDES 
Nitrosamides such as Diazald™ (N-methyl-N-nitroso-p-toluenesulfonamide) and Piltoy’s 
acid (N-hydroxybenzenesulfonamide) are convenient alternative nitrosating agents, especially 
when over exposure to NO gas may lead to multiple products. For example, Hughes and co-
workers66 reported the synthesis of mononuclear, and polynuclear iron nitrosyl complexes with 
the tripodal tetradentate  [N(CH2CH2S)3]3− ligand.  They found that NO gas reacted rapidly with 
(NEt4)[Fe(NS3)(CO)] to form (NEt4)[Fe(NS3)(NO)].  However, exposing the reaction mixture to 
NO gas for more than a few minutes led to insoluble products with multiple NO groups as 
indicated by several IR bands between 1600 and 1800 cm-1.  Preparation with Piloty’s acid in the 
presence of lithium methoxide or with Diazald™ produced the desired products without 
overnitrosation.   
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 2. REVIEW OF IRON NITROSYL COMPLEXES 
 
2.1. ENEMARK-FELTHAM NOTATION 
The remainder of this document utilizes the Enemark−Feltham notation11-13  to describe the 
MNO moiety in transition metal nitrosyl complexes. The Enemark−Feltham notation, {MNO}n, 
will be explained after a brief introduction to its inception. 
In the 1930’s Sidgwick recognized that, in bonding interactions with transition metals, 
nitric oxide, NO•, could lose an electron to form NO+ or gain an electron to form NO−.12,13,67 The 
valence bond structure for NO+ is has triple bond character (sp hybridized, linear), so Sidgwick 
proposed that NO+ complexes would exhibit a linear MNO group.  The valence bond structure 
for NO− has double bond character (sp2 hybridized, 120° bond angle), thus it was assumed that 
NO− complexes would exhibit a bent MNO bond.  In fact, the first linear MNO complexes 
characterized in the 1930’s were NO+; later, in the 1960’s, bent MNO NO− groups were also 
characterized.68 The available experimental evidence seemed to indicate that the charge on the 
NO group directed the MNO bond angle.  But, after more transition metal nitrosyl complexes 
were characterized, it became clear that something other than the charge on NO was directing the 
MNO bond angle.  Recognizing that metal nitrosyl complexes are highly covalent, Enemark and 
Feltham11-13  developed a system that accounts for the MNO angle based upon molecular orbital 
correlation diagrams.  The Enemark−Feltham approach treats each MNO group as a covalently 
bound entity which is sensitive to ligand field effects.  The method correlates molecular orbital 
orderings in various geometries, and considers how the character of the HOMO affects the 
geometry of the MNO group.11 The MNO moiety is bent when the HOMO is antibonding and 
linear when the HOMO is bonding.  In the Enemark−Feltham notation, {MNO}n, n represents 
11 
 the total number of metal d and NO π* electrons when NO is arbitrarily assigned as NO+.   The 
notation, which reflects the fact that there is significant mixing of metal d and π* NO orbitals, 
allows for some generalizations. For example, according to the Enemark−Feltham notation, six 
coordinate octahedral complexes with {MNO}6 are expected to be linear based upon molecular 
orbital correlation diagrams.  Exceptions occur and are understood by considering factors that 
influence the molecular orbital ordering, hence influence the MNO bond angle. The following 
sections describe factors influencing the MNO bond angles in iron nitrosyl porphyrins, porphyrin 
related complexes, dinitrosyl complexes, bimetallic nitrosyl complexes, cluster complexes and 
non-heme complexes. 
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 2.2. PORPHYRIN COMPLEXES 
Elucidation of the chemistry, structure and function of iron porphyrin nitrosyl complexes offers 
the promise of advances in medicine and a display of intriguing chemistry.  This section reviews 
some of the model complexes synthesized to study the chemistry and  structural features 
exhibited exhibited by iron nitrosyl porphyrins.10,69,70 
Thiolates react with bis(nitro)[α,α,α,α-meso-tetrakis(o-pivalamidophenyl)-porphinato] 
FeIII ([Fe(NO2)2(TpivPP)]) and 2,3,5,6-tetrafluorothiophenolate to produce the mixed ligand 
(thiolate/nitrite) FeIII complex [Fe(NO2)(SC6HF4)(TpivPP)]−. 71 On the other hand, 2,3,5,6-
tetrafluorothiophenol reacts with [Fe(NO2)2(TpivPP)] to yield the reduced (FeII(NO•)) product, 
[Fe(NO)(TpivPP)],  which exhibits a bent nitrosyl group, typical of {FeNO}7 complexes.  
[Fe(NO)(TpivPP)] was later converted, with exposure to air, to the nitrite complex, 
[FeIII(TpivPP)(NO2)(py)] in CHCl3 in the presence of pyridine.72 In the absence of pyridine, 
[Fe(NO)(TpivPP)]  oxidizes with air to the ferric chloro complex, [Fe(Cl)(TpivPP)].  Richter-
Addo and co-workers propose that pyridine assists stabilization of the nitrite product. This result 
has implications for iron nitrosyl reactivity in heme proteins bearing trans axial nitrogen bases.   
Iron-bound nitrite may be an intermediate or a product in some heme-NO ligand oxidations;72 
thus, release of coordinated NO may not be required for formation of NO2−, or NO3−. 
Whereas [M(OEP)(CO)] and [M(TTP)(CO)] (M = Ru, Os; OEP = octaethylporphyrinato 
anion; TTP = tetratolylporphyrinato dianion) form the corresponding [(por)M(NO)(SR)] and 
[(por)M(NO)(OR)] addition products, upon reaction with thionitrites (RSNO) and isoamyl nitrite 
(RONO), [(TPP)Fe(THF)2]+ reacts with isoamyl nitrate to produce the air sensitive and thermally 
unstable nitrosyl alcohol product [(TPP)Fe(NO)(HO-i-C5H11)]+  formally [FeIINO+]. Consistent 
with coordinated NO+, the X-ray crystal structure reveals a linear Fe-N-O linkage.   The 
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 thionitrite NO donor, S-nitroso-N-acetyl-L-cysteine methyl ester, reacts with [(TPP)Fe(THF)2]+ 
to form [(TPP)Fe(NO)] in high yield,  yet reacts with (OEP)Ru(CO) to form the trans addition 
product, (OEP)Ru(NO)(NACysMe-S),  (NACysMe-S = N-acetyl-L-cysteinate methyl ester) 
coordinated as a thiolate.73  
In related work, Ford and Lorkovic74 found that, upon exposure to NO gas,  [Ru(P)(CO)] 
(P = various porphyrins), forms [Ru(P)(NO)2].  The dinitrosyl then reacts with two equivalents 
of NO to give [Ru(P)(NO)(ONO)] and N2O.75-77  In contrast, [Fe(TPP)(NO)], formally {FeIINO•} 
is unreactive with NO in toluene and in chloroform at room temperature.  Instead, 
[Fe(TPP)(NO)] reacts with NO2 (N2O3) impurities in the NO gas stream to form 
[Fe(TTP)(NO)(NO2)].  This finding highlights the complications introduced by NOx impurities 
in NO gas and the fact that there are substantial kinetic differences between the reactivities of Fe 
and Ru porphyrins. 
 In the same study, it was also observed that NO dissociates more readily from 
[Fe(TTP)(NO)(NO2)], formally an {FeIII(NO•)(NO2−)} species, than does NO2.  Treatment of 
[K(222)][Fe(TpivPP)(NO2)] ( formed in situ from the reaction between [FeII(TpivPP)] and an 
excess of Kryptofix-222-solubilized KNO2; K(222) = potassium complex of 4,7,13,16,21,24 
hexaoxa–1,10-diazabicyclo[8.8.8]hexacosane) with gaseous NO yielded two crystalline forms of 
the FeII {FeNO}7 complex, [Fe(TpivPP)(NO2)(NO)]−. 78  The first form exists as two independent 
anion complexes.  One, shown in Figure 2.1, has ordered axial ligands.  The other, shown in 
Figure 2.2 has disordered axial ligands.  In each anion, the plane of the nitro group is almost 
perpendicular to the plane of the nitrosyl group.  Figure 2.3 shows form 2 in which the plane of 
the nitro group is nearly parallel to the plane of the nitrosyl.  The perpendicular orientation in the 
two complexes of form 1 allows each ligand to interact with distinct dπ orbitals, thus to bond 
14 
 more strongly to iron than does the parallel orientation of form 2 in which the ligands compete 
for π-bonding.  The nitrosyl group is bent in all three cases indicative of an [FeIINO•] 
assignment. These observations contrast with those for the nearly linear nitrosyl ligand of the 
diamagnetic FeIII, {FeNO}6 derivative of  [Fe(TpivPP)(NO2)(NO)].69  Here, the formal 
assignment is FeIII NO•, but a large FeII NO+ resonance contributor must also exist.  Two new 
synthetic methods were developed to prepare the FeIII derivative of [Fe(TpivPP)(NO2)(NO)].  In 
the same study tetraphenyl porphyrin (TPP), octaethyl porphyrin (OEP), tetra-p-methoxyphenyl 
porphyrin (TPP-(OMe)3) complexes were also synthesized and studied by Mossbauer and IR 
spectroscopies as well as by X-ray crystallography.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1   − ORTEP Diagram of [Fe(TpivPP)(NO2)(NO)]−  Form 1 Anion 1 
(30% probability ellipsoids)  The two ordered axial ligands have been labeled.  The angle between the NO2 and the 
FeNO planes is 85.4º.  (Reprinted with permission from J. Am. Chem. Soc., 1997, 119,  6274-6283. Copyright 1997 
American Chemical Society. 76) 
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Figure 2.2   − ORTEP Diagram of [Fe(TpivPP)(NO2)(NO)]−  Form 1 Anion 2 
(30% probability ellipsoids)  The disorder in the axial ligands is shown.  (Reprinted with permission from J. Am. 
Chem. Soc., 1997, 119,  6274-6283.  Copyright 1997 American Chemical Society. 76)  
 
 
 
 
 
Figure 2.3   − ORTEP Diagram of [Fe(Tpivpp)(NO2)(NO)]−  Form 2 
(30% probability ellipsoids).  The labels of the crystallographically unique atoms are shown along with the values of 
the bond distances in the coordination group.  The near parallel orientation of the nitrite ion plane and the iron-
nitrosyl plane is evident (the dihedral angle is 20.9º).  (Reprinted with permission from J. Am. Chem. Soc., 119, 
6274-6283. 1997, Copyright 1997, American Chemical Society. 76) 
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The related FeII complex, [FeII(TpivPP)(NO)], also forms along with 
[FeIII(TpivPP)(NO3)], in the reaction between BF3•OEt2 and the bis(nitro) complex of FeIII 
picket-fence porphyrin [K(18C6)(OH2)][Fe(TpivPP)(NO2)2] (18C6 = 1,4,7,10,13,16-
hexaoxacyclooctadecane).79 A possible pathway to the products is depicted in Figure 2.4.  
Initially, BF3•OEt2 acts as a Lewis acid to compete for one of the nitrite ligands of 
[Fe(TpivPP)(NO2)2]− and forms the mono(nitro)iron(III) complex along with a BF3-nitrite 
adduct.  The reactive mono(nitro)iron(III) complex, [FeIII(TpivPP)(NO2)] then disproportionates 
via oxygen atom transfer to [FeIII(TpivPP)(NO3)] and [FeII(TpivPP)(NO)].  Formation of crystals 
of [K(18C6)][BF3•NO3] suggests that [BF3NO2]− acts as a competitive O-atom acceptor.79  
 
[FeIII(TpivPP)(NO2)2]
- + BF3  OEt2 [Fe
III(TpivPP)(NO2)]  + (1)[BF3NO2]
-
2[FeIII(TpivPP)(NO2)] [FeIII(TpivPP)(NO3)]  + [Fe
II(TpivPP)(NO)] (2)   
Figure 2.4   − Formation of [FeIII(TpivPP)(NO3)] and [FeII(TpivPP)(NO)] 
(Reprinted with permission from Inorg. Chem., 1998 37, 2308-2316. Copyright 1998 American Chemical 
Society.77) 
. 
 
  A group of {FeNO}6 complexes, of formulation [Fe(NO)(OEP)L]+, was prepared by 
adding excess NO to solutions of [Fe(OEP)(OClO3)] and one of the neutral trans ligands 
illustrated in Figure 2.5.80 These are linear nitrosyl complexes, formally [FeII(NO)+]. The 
reaction was carried out under an NO atmosphere due to the extreme lability of the NO ligand.  
Crystals were also cultivated under an NO atmosphere using special techniques.  Scheidt and co-
workers had previously prepared the five-coordinate square-pyramidal {FeNO}7 complex, 
[Fe(OEP)(NO)] that  exhibited a well ordered, bent nitrosyl in two forms.  Figures 2.6 and 2.7 
display the crystal structures of forms one and two, respectively.  Each form shows an off axis 
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 Fe-NNO vector that is proposed to induce differences in the Fe-Np bond distances in both 
complexes.  An off axis tilt is suggested to be inherent to {FeNO}7 nitrosyl hemes.  Scheidt 
proposes that the structural distortions that result from the off axis tilts may be responsible for 
the difference in dissociation rates observed for the two forms of [Fe(NO)(OEP)].81   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5   − Neutral Trans Ligands for [Fe(NO)(OEP)L] Complexes 
(Reprinted with permission from J. Am. Chem. Soc. 1999, 121, 5210-5219. Copyright 1999 American Chemical 
Society. 78)
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Figure 2.6   − ORTEP Diagram of [Fe(OEP)(NO)] Form 1 
(50% probability ellipsoids)  (Reprinted with permission from J. Am. Chem. Soc. 1997, 119, 7404-7405. Copyright 
1997 American Chemical Society.79) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7   − Edge-on View of [Fe(OEP)(NO)] Form 2 
(Reprinted with permission from J. Am. Chem. Soc. 1997, 119, 7404-7405. Copyright 1997 American Chemical 
Society. 79) 
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Bohle et al. characterized octaethyltetraazaporphyrin complex [Fe(OETAP)(NO)] 
(OETAP = octaethyltetraazaporphyrin), which is isostructural to [Fe(NO)(OEP)]), by X-ray 
crystallography, IR, EPR, Mossbauer spectroscopies, electrochemistry and elemental analysis.82 
Physical and kinetic data can be seen in Table 2.1.  The increased reduction potential of the first 
oxidation couple, {FeNO}6-{FeNO}7 is a result of the electron withdrawing nature of the 
nitrogen atoms of the tetraaza derivative.   
 
Table 2.1 − Physical and Kinetic Data for [Fe(OEP)(NO)] and [Fe(OETAP)(NO)] 
(Chem. Commun., 1997, 91-92 - reproduced by permission of the Royal Society of Chemistry. 80) 
 
 
 
The X-ray crystal structure of [Fe(OETAP)NO], shown in Figure 2.8, reveals a bent 
nitrosyl, characteristic of {FeIINO•}7 complexes, which is oriented away from the ethyl groups 
on the same face of the complex.  In spite of almost identical steric constraints on axial ligand 
binding as compared to [Fe(OEP)(NO)], [Fe(OETAP)(NO)] dissociates NO four times faster 
upon treatment with pyridine or N-methylimidazole.  Differences in electronic character, as 
illustrated by the different Mossbauer and EPR spectra, are considered to be responsible for the 
different reactivities. 
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gure 2.8   − Molecular Structure of [Fe(OETAP)(NO)] 
hown with hydrogen atoms omitted for clarity.  Important bond lengths (Å) and angles (º): Fe(1)-N(1-4) 1.922-
N(9)-O(1) 143.7(4).  (Chem. Commun., 1997, 91-92 - 
Fi
S
1.941(3),  Fe(1)-N(9), 1.721(4), N(9)-O(1) 1.155(5); Fe(1)-
reproduced by permission of the Royal Society of Chemistry 80) 
 
 
83cheidt  and co-workers also compared the newly synthesized [Fe(OEP)(NO)]ClO4, formally an S
[FeII(NO+)] or {FeNO}6 linear nitrosyl,  with that of a previously reported solvated form, 
[Fe(OEP)(NO)]ClO4•CHCl3. The data displayed in Table 2.2 highlights some important 
differences in bond angles, distances and stretching frequencies between [Fe(OEP)(NO)]ClO4 
and [Fe(OEP)(NO)]ClO4•CHCl3 as well as differences relevant to the cofacial dimers formed by 
both forms in the crystalline state. One important difference is the 30 cm-1 difference in the IR 
stretching frequency with v NO at 1868 cm-1 for [Fe(OEP)(NO)]ClO4•CHCl3 and v NO at 1838 
cm-1 for [Fe(OEP)(NO)]C Ol d
 
4.  The origin of this difference was investigate  by X-ray 
crystallography, Mossbauer spectroscopy and electrochemical methods.  The ORTEP diagram of 
[Fe(OEP)(NO)]ClO4 in Figure 2.9 reveals a nearly linear Fe-N-O (173.19(13)°) group which is 
consistent with that determined for  [Fe(OEP)(NO)]ClO4•CHCl3 (176.9(3)°).   
 
21 
  
Table 2.2 − Selected Comp
02-5110. Copyright 2000, American Chemical Society. 
arisons for [Fe(OEP)(NO)]+   
(Reprinted with permission from Inorg. Chem., 39, 2000, 51
81) 
 
 
 
 
 
igure 2.9   − Crystal Structure of [Fe(OEP)(NO)]ClO4
s are contoured at the 50% probability level.  The labeling 
 
 
F
The closest perchlorate anion is shown.  Thermal ellipsoid
scheme is also shown.  (Reprinted with permission from Inorg. Chem., 39, 2000, 5102-5110. Copyright 2000, 
American Chemical Society. 81) 
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 The ORTEP diagrams of the cofacial dimers of each complex (Figure 2.10) show that,  
ssentially 
 
while the nitrosyl group in [Fe(OEP)(NO)]ClO4 (B) tilts 4.6° from the heme normal, e
no tilt is observed for the solvated form [Fe(OEP)(NO)]ClO4•CHCl3 (D).  The slight difference 
in the tilting of the nitrosyl is group is the most glaring reason for the difference in stretching 
frequency.  The off axis tilt in the direction of the bend is consistent with the conclusions of 
Ghosh and Bocian84 who have illustrated that CO tilting is strongly  coupled with CO bending in 
monoxyheme.   In fact, all well characterized {FeNO}7 porphyrin species exhibit such tilting and 
bending; it has been suggested that tilting allows better overlap between the π* orbital of NO and 
the dz2 orbital of the metal.81,85 Figure 2.1285 illustrates the greater π*NO - dz2 orbital overlap 
achieved by tilting of dz2 orbital. The existence of both forms of these {FeNO}6 porphyrin 
complexes suggests that the stabilization gained by tilting and bending is insufficient to cause 
titling in all cases.  The difference in v NO may also arise from differences in how the cations 
interact to form crystalline dimers.  Figure 2.10 reveals that the porphyrinato nitrogen of 
[Fe(OEP)(NO)]ClO4•CHCl3 is located almost directly above the iron atom of the closest 
molecule. For the CHCl3 solvated complex, the iron center may adopt this extra interaction from 
the next plane as a sixth ligand. A sixth ligand would reduce tilting and as a result, increase 
stretching frequency. This contact is lacking in the unsolvated [Fe(OEP)(NO)]ClO4 which has no 
pseudo sixth ligand.  Another interesting feature of these two different crystalline forms is 
asymmetric Fe-Np bonds which seem to correlate with the off axis tilt of the nitrosyl.  Figure 
2.1185 shows how the two equatorial bonds in the direction of the tilt shorten while those in the 
opposite direction lengthen. Scheidt and co-workers explain the correlation of tilting with bond 
shortening based upon an observation first noted by Hoffman.  Hoffman suggested that the tilting 
observed in some square pyramidal {MNO}8 complexes could be caused by the increased 
23 
  
 
 
 
 
 
 
 
 
 
igure 2.10 − ORTEP Diagrams of the Two Cations in [Fe(OEP)(NO)]ClO4
) view perpendicular to the mean porphyrin plane and (B) view parallel to the mean porphyrin plane.  ORTEP 
iagrams of the two closely interacting cations of the solvated form [Fe(OEP)(NO)]ClO4•CH3Cl; (C) view 
erpendicular to the mean porphyrin plane and (D) view parallel to the mean porphyrin plane.  The differences in 
ted with permission from 
. 81
 
 
 
 
 
F
(A
d
p
the bendings and tiltings of the nitrosyl groups are readily seen in views B and D. (Reprin
Inorg. Chem., 39, 2000, 5102-5110. Copyright 2000 American Chemical Society ) 
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igure 2.11 − Correlated Tilt/Asymmetry in Five-coordinated [Fe(Porph)(NO)] Derivatives 
orrelated tilt/asymmetry in five-coordinated [Fe(Porph)(NO)] derivatives. The two equatorial Fe-Np bonds to the 
ght (in the direction of the tilt) are shortened, while the Fe-Np bonds to the left are lengthened.  The magnitudes of 
e distortion have been exaggerated for clarity.  (Reprinted with permission from J. Am. Chem. Soc. 2000, 122, 
 
F
C
ri
th
4651-4659. Copyright 2000, American Chemical Society.83) 
 
 
overlap between the metal dz2 and one π*NO orbital that is achieved upon NO bending 
concomitant with sideways motion of the nitrosyl as depicted in Figure 2.12.85,86  The tilting 
f
σ
observed by Hoffman, however, is in the direction opposite that observed for 
[Fe(OEP)(NO)]ClO4•CHCl3 and [Fe(OEP)(NO)]ClO4.  The model suggested by Scheidt and co-
workers involves an alternative way to increase dz2 and π*NO overlap.  This model, also depicted 
in Figure 2.12, allows a rotation of the metal dz2 orbital which leads to a tilt in the direction 
opposite of that observed by Hoffman.  In addition, rotation of the metal dz2 orbital with respect 
to the porphyrin plane changes the σ interactions o  the metal dz2 orbital with the porphyrin when 
the metal ion is out of the porphyrin plane, as it is in these complexes.  The  interactions in the 
direction of the tilt will be enhanced, whereas those in the opposite direction will be weakened. 
Mossbauer measurements confirm a diamagnetic ground state.  
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gure 2.12 − Possible Distortions Leading to Greater Overlap of π*NO with Iron dz
ossible distortions lead to two different tilt directions. (Reprinted with permission from J. Am. Chem. Soc. 2000, 
22, 4651-4659. Copyright 2000, American Chemical Society. 83
Fi
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Unusual quadrupole splitting and isomer shifts (for low spin FeIII) porphyrins are 
z  = i 83 III
)
−
 
observed for [Fe(OEP)(NO)]ClO4•CHCl3, [Fe(OEP)(NO)]ClO4, and [Fe(OEP)(Iz)(NO)]ClO4   
(I midazole).  Scheidt and co-workers view these species as low spin [Fe NO•] and argue 
this case from Mossbauer data.  Similar complexes studied by Scheidt are [Fe(TPPBr4)(NO ] 
(TPPBr4 = 2,3,12,13-tetrabromo-5,10,15,20-tetraphenylporphyrin dianion) and 
[Fe(oxoOEC)(NO)] (oxoOEC = 3,3,7,8,12,13,17,18-octaethyl-3H-porphin-2-onato(2 ) 
dianion).85  Related iron and ruthenium porphyrin complexes, (OEP)Fe(NO)(p-C6H4F) and 
(OEP)Ru(NO)(p-C6H4F) exhibit strongly bent and tilted M-N-O units as well as elongated M-
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 N(NO) bonds.87 The authors view these species as {MIIINO•}6 (MIII = FeIII and RuIII) that yield 
bent nitrosyls due to very strongly σ donating ligands trans to NO•.  In this case the trans ligands 
are strong carbon donors.  Figures 2.13 and 2.1487 illustrate the bent and tilted nitrosyl group in 
both complexes; Table 2.387 displays selected bond angles and bond distances for each complex.  
Richter-Addo and co-workers suggest that bending of the M-N-O group is inherent to 
(por)M(NO)(p-C4H4F) when X is a strong σ donor.  Hybrid Hartee-Fock/density functional 
calculations reveal that a minimum energy structure exists with a bent NO group and with both 
the NO and the p-C6H4 ligands tilted off axis.  The calculated values approximate the observed 
N-O, Fe-NO, and Fe-Np bond distances as well as the observed tilt angles and the extent of NO 
bending. Theoretical values are compared with experimental values in Figure 2.15.   
Extended Huckel calculations suggest that bending of the FeNO moiety to bisect an Np-
Fe-Np angle provides a lower energy barrier than bending in a direction that eclipses an 
equatorial Fe-Np bond.  This is because bending that bisects an Np-Fe-Np angle avoids interaction 
between the NO π* orbital and the metal dx2-y2 orbital. Figure 2.16 displays the molecular orbital 
energy level diagram of (porph)Fe(NO)(p-C6H4F) as well as the B2 symmetry LUMO and the A2 
symmetry HOMO.  Figure 2.17 illustrates how the 2A1 and 1B1 orbitals mix upon bending to 
hybridize the metal contribution such that it maintains a strong bonding interaction with the NO 
π* orbital.  Figure 2.18 depicts the way nitrosyl bending causes mixing of nitrogen and oxygen  
pz character to enhance the bonding interaction of the metal and the nitrosyl.  In addition, upon 
tilting the dxz component maintains a favorable interaction with the porphyrin π system. Richter-
Addo and coworkers have provided tables of selected comparisons for axial bonding parameters 
for several {MNO}6 and {MNO}7 metalloporphyrins as well as for IR stretching frequencies for 
{FeNO}6 and {RuNO}6 complexes. Results of Mossbauer spectroscopic investigations suggest 
27 
 that bending can be expected when strong σ donors are trans to the nitrosyl group.  Stong σ 
donors trans to the nitrosyl group automatically stabilize the MIII state, hence the assignment 
[MIIINO•]. Extended Huckel calculations show that bending to bisect an Np-Fe-Np angle is 
energetically favorable to eclipse an Fe-Np bond.  These results suggest that the convention that 
assumes a linear MNO linkage for ferric nitrosyl hemes needs to be changed to account for the 
low energy bending and axial tilting exhibited by these unprecedented strongly bent {FeNO}6 
complexes. 
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Figure 2.13 − Molecular Structure of (OEP)Fe(NO)(p-C6H4F) 
(a) Molecular structure of (OEP)Fe(NO)(p-C6H4F). Hydrogen atoms have been omitted for clarity. (b) Top view 
(perpendicular to the porphyrin plane) showing the orientation of the axial groups with respect to the porphyrin 
skeleton.  (c) Perpendicular atom displacements from the 24-atom porphyrin plane (in 0.01 Å units). (Reprinted with 
permission from J. Am. Chem. Soc. 2001, 123, 6314-6326. Copyright 2001, American Chemical Society. 85) 
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Figure 2.14 − Molecular Structure of (OEP)Ru(NO)(p-C6H4F) 
(a) Molecular structure of (OEP)Ru(NO)(p-C6H4F). Hydrogen atoms have been omitted for clarity. (b) Top view 
(perpendicular to the porphyrin plane) showing the orientation of the axial groups with respect to the porphyrin 
skeleton.  (c) Perpendicular atom displacements from the 24-atom porphyrin plane (in 0.01 Å units). (Reprinted with 
permission J. Am. Chem. Soc. 2001, 123, 6314-6326. Copyright 2001 American Chemical Society. 85) 
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Table 2.3 − Selected Bond Lengths and Angles for (OEP)M(p-C6H4F) M = Ru, Fe 
(Reprinted with permission from J. Am. Chem. Soc. 2001, 123, 6314-6326, Copyright 2001, American Chemical 
Society. 85) 
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Figure 2.15 − Selected Geometrical Parameters for (porph)Fe(NO)(p-C6H4F) 
Selected geometrical parameters (in Å and °) calculated by using the B3LYP hybrid Hartree-Fock/density functional 
method, compared with corresponding parameters for (OEP)Fe(NO)(p-C6H4F), determined by X-ray diffraction (in 
parentheses).  The tilting angles and atom displacement (Δ) are with respect to the four nitrogen porphyrin plane.  
(Reprinted with permission from J. Am. Chem. Soc. 2001, 123, 6314-6326. Copyright 2001, American Chemical 
Society. 85) 
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Figure 2.16 − Molecular Orbital Diagram of (porph)Fe(NO)(p-C6H4F) 
Molecular orbital energy level diagram of (porph)Fe(NO)(p-C H F) The B symmetry LUMO and the A symmetry 
HOMO are also shown. (Reprinted with permission from J. Am. Chem. Soc. 2001, 123, 6314-6326. Copyright 2001, 
American Chemical Society. 
6 4 2 2 
85) 
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Figure 2.17 − Orbitals 1B1 and 2A1  
Orbitals 1BB1 and 2A1 mix upon tilting axial ligands to give the orbital shown on the right. (Reprinted with 
permission from J. Am. Chem. Soc. 2001, 123, 6314-6326. Copyright 2001, American Chemical Society. 85) 
 
 
 
 
 
 
 
Figure 2.18 − Bending of the Nitrosyl Ligand 
Bending the nitrosyl ligand mixes nitrogen (and oxygen) Pz character into the orbital shown on the left to better 
aligns the nodes on the NO π* and metal d orbitals, as shown on the right. (Reprinted with permission from J. Am. 
Chem. Soc. 2001, 123, 6314-6326. Copyright 2001 American Chemical Society. 85) 
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 Metalloporphyrin nitrosyl complexes also exhibit linkage isomerization.  While the 
nitrosyl group usually binds η 1 through the nitrogen atom, it has been observed to bind via the 
oxygen atom. The first low temperature infrared spectroscopic evidence for photo-induced 
metastable η1-O and η2-NO linkage isomers of the group 8 {MNO}6  (linear) nitrosyl 
metalloporphyrins, [(OEP)Ru(NO)(L)], (L = O-iC5H11, SCH2CF3, Cl) and [(OEP)Ru(NO)(py)]+ 
was reported by Coppens, et al.88 Coppens and co-workers later reported the first spectroscopic 
and theoretical evidence of linkage isomerism for bent MNO. The five coordinate {MNO}7  iron 
nitrosyl porphyrins, [Fe(OEP)(NO)] and [Fe(TPP)NO] produce [Fe(OEP)(η1-ON)] and 
[Fe(TTP)(η1-ON)] as low-temperature photoproducts89  Ground state optimization of 
[Fe(OEP)NO] by Bagley et al.89 reproduced the structural distortions reported by Scheidt and co-
workers81,85 and previously discussed in this thesis.   
 
Figure 2.19 − NO Linkage Isomers 
(Reprinted with permission from J. Am. Chem. Soc. 2001, 123, 5680-5683. Copyright 2001 American Chemical 
Society. 88)
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 Wondimagegn and Ghosh90 completed a quantum chemical survey of the η 1-ON,  
η 1-NO, η 2-NO linkage isomers as well as of the structural distortions induced by tilting of the 
MNO bond in conjunction with bending of the MNO group observed by Scheidt.  Figure 2.1990 
illustrates the various linkage isomers and the out of phase tilted and bent isomer observed by 
Scheidt and co-workers.85 Density functional theory (DFT) calculations were completed for 
[M(P)(NO)] (M = Mn, Fe, Ru, Co, Rh), [M(P)(NO)]+ (M = Fe, Ru), [M(P)(N)(imidazole)]+  (M 
= Fe, Ru) and [M(P)(NO)(L)] (M = Fe, Ru; L = Cl, Ph, SCH3).90  Table 2.4 shows the relative 
energies of the η 1-ON, η 1-NO, η 2-NO linkage isomers.  The global minimum for each complex 
was calculated to be the η 1-NO isomer. The η 1-ON isomer exists at 1.06-1.47 eV higher in 
energy than the η 1-NO isomer, therefore, η 1-ON isomer, formed by photoexcitation processes, 
is expected to be metastable at 77 K or lower, and to return to the η 1-NO form upon warming.  
Isonitrosyl complexes Fe(TTP)(η 1-ON) and Fe(OEP)(η 1-ON) were also observed as low 
temperature photoproducts.89  While optimized η 1-ON isomers were obtained for all complexes 
by Wondimagegn and Ghosh (Table 2.490), the η 2 linkage isomers were theoretically established 
only for Mn(P)(NO), [Fe(P)(NO)]+, Ru((P)(NO)Cl, [Ru(P)(NO)(L)]+ (L = no ligand, imidazole, 
and pyridine).  These calculated results are consistent with the experimental observations of 
Coppens and co-workers.88 The implication is that an {MNO}6 electron count contributes to the 
stabilization of η 2 coordinated nitrosyl groups.  This same conclusion has been drawn by 
Coppens et al. with respect to photo-induced metastable linkage isomers of nonporphyrin 
transition metal complexes.91 Wondimagegn and Ghosh explain, that the LUMO of 
[Fe(P)(NO)]+, depicted in Figure 2.20,90 is both bonding and antibonding with respect to the 
metal dz2-NO(π*) interaction.  Upon addition of an electron to this molecular orbital, as in 
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Table 2.4 − Energetics (eV) of Different Metalloporphyrin-NO Linkage Isomers   
Energetics (eV) of Different Metalloporphyrin-NO Linkage Isomersa,b   (Reprinted with permission from J. Am. 
Chem. Soc.  2001, 123, 5680-5683. Copyright 2001 American Chemical Society. 88) 
 
 
 
 
 
 [Fe(P)(NO)]0 the MNO unit will open to maintain only the bonding dz2 – NO(π*) interaction.  
Hence, attempts to optimize [Fe(P)(η2-NO)(L)]0 (L = Cl, Ph, SCH3), [Fe(P)(η2-
NO)(imidazole)]+, and [Ru(P)(η2-NO)(L)] (L = Ph, SCH3) yielded partially ring-opened MNO 
geometries with MN(O) and NO vectors oriented in opposite directions with respect to the heme 
normal.  This result is pertinent to results obtained from a high resolution X-ray crystallographic 
analysis92 of nitrophorin 4, a nitric oxide binding heme protein discovered in the blood sucking 
insect Rhodnius prolixus.  Montfort and co-workers observed two distinct NO conformations, 
one with a relatively upright orientation and another in which the FeN(O) and NO vectors were 
tilted in opposite directions with respect to the heme normal.  The authors suggest that this 
unusual out-of phase tilted and bent orientation, shown in Figure 2.2090,93 may correspond 
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Figure 2.20 − The [Fe(P)(NO)]+ LUMO is Bonding and Antibonding
(Reprinted with permission from J. Am. Chem. Soc., 2001, 123, 5680-5683. Copyright 2001 American Chemical 
Society. 88) 
 
to a loosely bound or to an η2-NO.  The theoretical calculations and experimental evidence 
indicate that the “out of phase titled and bent FeNO geometries do correspond to true local 
minima on the potential energy surfaces of these molecules.”90  Thus, the in phase titled and bent 
geometries and the out-of-phase tilted and bent geometries may represent examples of “bond 
angle isomerism.”90  The {MNO}7 and {MNO}8 η 2-NO complexes open upon optimization to 
give only in phase titled and bent η 1 geometries.   
Morishima et al.94 have conducted model studies of dissimilatory nitrite reductase, which 
catalyzes single-electron reduction of nitrite, mostly to nitric oxide, and under appropriate 
conditions to nitrous oxide.  There have been attempts, some successful, to mimic the function of 
metalloenzymes, such as nitrate reductase, by incorporating iron porphyrins into polymeric 
films.95-98  The ultimate goal is to utilize electropolymerized metalloporphyrins as electrode 
materials for chemical and biological sensors. Nitrite reductase comprises two subunits which 
contain hemes c and  d1.  Heme d1 is the preferential binding and catalytic site of nitrite  
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Figure 2.21 − Proposed Structure for Dioxobacteriochlorin (heme d1) 
(Reprinted with permission from Inorg. Chem., 1995, 34, 6362-6370. Copyright 1995 American Chemical Society. 
92)
 
 
reductase.  A proposed structure for Heme d1 is that of iron dioxoisobacteriochlorin, illustrated in 
Figure 2.21.94   
An [Fe(NO)]  nitrosyl complex has been proposed by Kim and Hollocher to form as an 
intermediate via dehydration of NO  to NO during the reduction cycle (Figure 2.22) by 
dissimilatory nitrite reductase.  The [Fe(NO)] , produced in the proposed catalytic cycle, has
+ 99
2
−
+   
three possible valence isomers, the paramagnetic [FeII(NO) π-cation radical], and the 
diamagnetic isomers, [FeIII(NO)], and [FeII(NO+)].  Clearly, the electronic configuration of  
[Fe(NO)]+ plays a crucial role in the reduction of NO2− to NO.  Morishima et al.100 initially 
prepared FeII(NO) cation radical complexes via oxidation of oxooctaethylchlorin (oxo-OEC) and 
2,3,7,8-dioxooctaethylisobacteriochlorin (dioxo-OEiBC) in order to learn more about the 
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Figure 2.22 − Proposed Dissimilatory Nitrite Reductase Catalytic Cycle 
(Reprinted with permission from Inorg. Chem., 1995, 34, 6362-6370. Copyright 1995 American Chemical Society. 
92) 
 
character of [Fe(NO)]+.  In a follow-up study, Morishima and co-workers94 reported that the one-
electron oxidation of (OEP)FeII(NO), (oxo-OEC)FeII(NO) and (dioxo-OeiBC)FeII (NO), 
illustrated in Figure 2.2394 form formally [Fe(NO)]+ oxidation products.  Electronic absorption, 
ESR, NMR and IR spectroscopies reveal that the one-electron oxidation product of (oxo-
OEC)FeII(NO) and (dioxo-OeiBC)FeII(NO) is the π−cation radical, which exhibits a bent FeNO 
moiety, while the one-electron oxidation product of (OEP)FeII(NO) is an FeIII(NO) complex with 
a nearly linear Fe-NO unit.  In the same investigation, it was found that valence isomerization 
 which occurs upon ligation of N-methyl imidazole to the cation radicals,  [(oxo-OEC+)FeII(NO)]    
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Figure 2.23 − [(OEP)FeII(NO)]+, [(oxo-OEC)FeII(NO)]+, [(dioxo-OeiBC)FeII(NO)]+
(Reprinted with permission from Inorg. Chem., 1995, 34, 6362-6370. Copyright 1995 American Chemical Society. 
92 ) 
 
 
and [(dioxo-OeiBC+)FeII(NO)], yields the respective FeII(NO+)(N-MeIm) complexes which 
readily release NO in the presence of additional N-MeIm. The possible structures for the valence 
isomers are illustrated in Figure 2.24. Morishima et al.94 link the facile release of NO from (oxo-
OEC)FeII(NO+) and (dioxo-OeiBC) FeII (NO+) in the presence of  N-MeIm to the presence of 
oxo groups, on the porphyrin ring, which increase the positive charge on iron and deplete the 
extent of Fe(dπ)-NO(π*) backbonding.  The (OEP)FeII(NO) derivative lacks oxo groups, thus 
requires almost four moles of N-MeIm for complete formation of the  
 
 
Figure 2.24 − Valence Isomerization Upon Addition of N-Methyl Imidazole 
(Reprinted with permission from Inorg. Chem., 1995, 34, 6362-6370. Copyright 1995 American Chemical Society. 
92) 
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 corresponding iron(III)bis(imidazole) complex.  Morishima et al. suggest that the NO bound 
heme d1 in nitrite reductase forms the intermediate FeII(NO+)(L).  The ready release of NO in the 
reaction with N-MeIm suggests ligation of a distal histidine or a nucleophilic amino acid residue 
to initiate NO release in the enzyme.  In fact tyrosine in the distal pocket has been shown to 
ligate to heme d1.101   Morishima et al. also conclude that it is likely that the presence of the oxo 
groups on heme d1 influence NO release from the [FeIINO+] intermediate and influence the redox 
properties of the metal center thus facilitate use of heme d1 in dissimilatory nitrite reductases. 
Ryan and Liu102 used pulse polarography and cyclic voltammetry103 to  investigate the 
kinetics for the reduction of iron porphyrin nitrosyls to ammonia by assimilatory nitrite 
reductases using the following model complexes: Fe(TTP)(NO), Fe(OEP)(NO), Fe(2,4-
DMOEiBC)(NO),  (2,4-DMOEiBC=2,4-methyloctaethylisobacteriochlorin), Fe(oxo-OEC)(NO) 
and Fe(MOEC)(NO) (MOEC = methyloctaethylchlorin).  The siroheme model complex Fe(2,4-
DMOEiBC)(NO) exhibited the most facile formation of Fe(P)(NH2O+); the dissimilatory nitrate 
reductase model complex Fe(2,4-dioxo-OEiBC)(NO) formed the intermediate Fe(P)(NH2O+) 
least readily. In non-aqueous solvents and in the presence of weak acids  NH2O+ is released as 
NH2OH. NH2OH is reduced to NH3 is the presence of iron porphyrins. The authors conclude that 
the macrocycle influences the rate at which NO is reduced to NH3. 
Chen and Ikeda104 reported  that [FeIII(TMPyP)]5+ (TMPyP = meso-tetra(N-methyl-4-
pyridyl) porphyrin) catalyzes the oxidation of NO to NO2- in a phosphate buffer solution at pH = 
7.4 at a current that is ten times  higher than that for FeIII phosphate in solution without the 
porphyrin.  This current is large enough to be useful in a chemical sensor that can be used in 
oxygen containing physiological environments because oxygen is electroinactive at positive 
potentials.  The oxidation-reduction mechanism in Figure 2.25104 was proposed. 
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Figure 2.25 − The Oxidation-Reduction Mechanism of NO with [Fe(TMPyP)]5+
The oxidation-reduction mechanism of NO with water soluble iron porphyrin, [Fe(TMPyP)]5+ (Reprinted with 
permission from Electroanalysis, 2001, 13, 1076-1081.  Copyright 2001 John H. Wiley and Sons, Inc. 102) 
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 2.3. METALLOPORPHYRIN RELATED IRON NITROSYL COMPLEXES  
Because NO binds FeII porphyrins for the activation of guanylate cyclase and in equilibria related 
to biological clearance pathways, it is important to understand how the bonding interaction 
between Fe(II) porphyrins and NO differs from that between Fe(II) porphyrins and CO or O2. 
Since the unsaturated macrocyclic water soluble FeII complex , [Fe(TIM)(CH3CN)2(PF6)2] (TIM 
= 2,3,9,10-tetramethyl-1,4,8,11-tetraazacyclodeca-1,3,8,10-tetraene) satisfies some of the criteria 
as a possible NO scavenger,105  Shepherd and Chen106 presented a comparison between how NO, 
CO and O2 bind to the macrocyclic TIM complex and  to a porphyrin complex.  Their paper also 
reports the reversible coordination of NO to [Fe(TIM)(CH3CN)2],2+ its characterization as a six 
coordinate nitrosyl, similar to FeII porphyrin nitrosyls in its EPR behavior, and its differing 
stability in CH3CN, CH3CN/CH3OH, CD3OD and D2O.  
The equilibrium described in figure 2.26 was established by exposing a solution of 
[Fe(TIM)(CH3CN)2(PF6)2] (ca. 3 × 10-3 M) in Ar purged CH3CN, to nitric oxide gas for twenty 
minutes.  Spectral data (λ = 390 nm, ε = 1.59 × 103 M-1 cm-1)  reveal that 53 % of the initial 
[Fe(TIM)(CH3CN)2(PF6)2] was converted to the nitrosyl adduct.  Assuming a first order 
dissociation of NO, in CH3CN [Fe(TIM)(CH3CN)(NO)]2+ exhibits a dissociation rate constant of 
kd = 3.85 × 10-3 s-1 by N2 purging.  The EPR spectrum of [Fe(TIM)(CH3CN)2(NO)]2+, obtained in 
60 % CH3OH/40 % CH3CN at 77K, and shown in figure 2.27, exhibited three features with g = 
2.01, 1.99 and 1.97, indicative of an S = ½ {FeNO}7 complex.  Only the center line near g = 2 
exhibited N-shf (shf – super hyperfine)  structure indicating the presence of only one coordinated 
NO ligand.  This behavior is similar to that of the heme nitrosyl complexes in which the heme 
macrocycle produces strong field NO complexes of  S = ½.107-109 Hemoglobin and myoglobin 
nitrosyls exhibit splitting of the middle or third component of the g features near g = 2.110,111   
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 Splitting of the middle feature by N-shf indicates a six-coordinate low-spin FeII nitrosyl;107,109  
splitting of the third component indicates a five-coordinate low-spin FeII nitrosyl.  Thus, the  
Fe(TIM) complex must have either an axial CH3CN or CH3OH, since the middle line exhibits N- 
shf  structure.  
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Figure 2.26 − [Fe(TIM)(CH3CN)2]2+ and [Fe(TIM)(CH3CN)(NO)]2+ 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
 
 
 
Figure 2.27 − EPR Spectrum of [Fe(TIM)(CH3CN)2(NO)]2+
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
 
45 
 Previous studies106 have shown that the use of mixed solvents lowers the activity of 
CH3CN and favors the addition of nitrogen base donors.  When a sample of 
[Fe(TIM)(CH3CN)2(PF6)2] was prepared in 60% CH3OH/40% CH3CN (vol./vol.) the amount of 
coordinated NO increased from 53.1% (100% CH3CN) to 80.7%.  The band in the visible 
spectrum representing the nitrosyl complex occurred at 390 nm as it did in CH3CN, this time 
with an extinction coefficient of 2.19 × 103 M−1 cm−1. 
The electronic spectrum changes when axial CH3CN ligands are replaced with H2O or 
CH3OH.  The extent of CH3CN dissociation from [FeII(TIM)]2+  in  H2O  is concentration 
dependent as shown in Figure 2.28.  At 3.06 × 10−4 M in a 1.00 cm cell Spectrum A in Figure 
2.28 exhibits a major peak at 646 nm and a shoulder at 575 nm.  Spectrum B in Figure 2.28 is 
that of more concentrated 3.06 × 10−3 M solution which shifts the equilibrium described in the 
equation below to the right in response to the higher concentration of liberated CH3CN. 
[Fe(TIM)(H2O)2]
2+  +  CH3CN [Fe(TIM)(CH3CN)(H2O)]
2+
KCH3CN
 
 
Figure 2.28 − Visible Spectrum of [Fe(TIM)(CH3CN)2](PF6)2 in H2O 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
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 1H NMR studies verified the existence of a stable [Fe(TIM)(CH3CN)(H2O)]2+  complex in the 
presence of sufficient CH3CN.  If there is an insufficient concentration of CH3CN to completely 
form the mono CH3CN adduct, the [Fe(TIM)( H2O)2]2+  complex slowly decomposes under Ar at 
room temperature as shown by Figure 2.29, as well as by 1H NMR studies.  1H NMR data also 
revealed that decomposition of the [Fe(TIM)(H2O)2]2+ complex was strongly retarded by the 
presence of an axial π-acceptor ligand, such as NO, CO, or CH3CN, trans to H2O.  That the  
[Fe(TIM)(CH3CN)(NO)]2+  complex forms more slowly than does [Fe(TIM)(CH3CN)(H2O)]2+ 
complex, implies that NO adds on a displacement of H2O in the mono acetonitrile product. 
Purging experiments to establish reversibility in H2O were complicated by an O2/NO reaction in 
which trace NO2 forms and rapidly oxidizes [FeII(TIM)]2+ thus rendering the starting spectrum A 
in figure 2.30 unrecoverable with N2 purging.  However, some of the [Fe(TIM)(CH3CN)(H2O)]2+  
regenerates in the presence of sufficient CH3CN. Assuming a first-order dissociation of NO, a 
dissociation rate constant in CH3CN, where reversibility occurs, was calculated from the time 
required for complete removal of NO from the [Fe(TIM)(CH3CN)(NO)]2+  by N2 purging to be kd 
= 3.85 × 10-3 s –1.  NO dissociation from [Fe(TIM)(H2O)NO]2+ via Ar or N2 purging was 
complicated by oxidation pathways previously described.  In addition, the subsequent 
decomposition steps for  [Fe(TIM)(H2O)2]2+, shown in Figure 2.31, occur more rapidly than does 
NO dissociation;  thus, decomposition products, rather than [Fe(TIM)(H2O)2]2+ are observed.  
Solubility and side reactions in H2O limit the viability of   [Fe(TIM)(CH3CN)2(PF6)2] as an NO 
scavenger for the treatment of sepsis. 
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Figure 2.29 − [Fe(TIM)(CH3CN)2](PF6)2 Decomposition in H2O 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
 
 
 
 
 
 
Figure 2.30 − Visible Spectrum of Reaction of [Fe(TIM)(CH3CN)2](PF6)2 with NO 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
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Figure 2.31 − Decompostion Pathways for [Fe(TIM)CH3CN)2](PF6)2 in H2O 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
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Table 2.5 − Estimated CO and NO Binding Constants 
(Reprinted from Inorg. Chim. Acta, 260, Ya Chen, Michael A. Sweetland and Rex E. Shepherd*, “A reversible NO 
complex of FeII(TIM):  an S = ½ {FeNO}7 nitrosyl”, 163-172, Copyright 1997, with permission from Elsevier. 104) 
 
 
The binding constants in Table  2.5112-114 show that, in general, NO binds more strongly 
to Fe(II) porphyrins than does CO.  Studies with model complexes have suggested that the linear 
Fe-CO bond causes peripheral globin and porphyrin interactions.  Bent Fe-NO and Fe-O2 
moieties minimize these peripheral interactions.  Therefore binding to NO or to O2 is sterically 
favored over binding to CO for the porphyrins.  Shepherd and Chen’s106 results reveal that, in 
contrast to Fe(II) porphyrin complexes, in CH3CN, CO coordination is slightly favored over NO 
coordination to the FeII TIM macrocycle.  The relative association constant KNO/KCO is ~ 0.46.   
As previously mentioned, peripheral interactions explain the KNO/KCO ratio (≥ 1100) for 
porphyrins in the presence of a trans axial base.  For the TIM complex the absence of linear 
perturbations is expected to remove the hindrance component to CO coordination.  Models 
reveal that the β-CH2 units of the TIM ligand closely approach the axial position. Consequently, 
the bent S = ½ NO group, will interact more with the flexing CH2 hydrogens than will a linear 
CO group.  This idea is consistent with the observation that the [Fe(TIM)(CH3CN)NO]2+ 
complex will be relatively less stable than its CO analogue, opposite the case for the 
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 [FeII(porphyrin)(base)NO] complexes compared to their CO analogues. With the [Fe(TIM)]2+  
system, removal of the hindrance to CO coordination along with incorporation of steric contacts 
for NO lowers KNO/KCO below one.  It is reasonable that the formation constants KNO and KCO 
would be smaller for the [FeII(TIM)(CH3CN)]2+ species than for the related [FeII(heme)] as 
illustrated by the data in Table 2.5.  Electrochemical data that  show that E´°  for the 
methemoglobin/hemoglobin couple, at 0.17 V versus NHE,115 is less than that for the FeII/III 
couple for the [Fe(TIM)(CH3CN)2]2+, at 0.83 V versus NHE; the FeII center is more stabilized by 
the TIM/CH3CN environment than by the heme system.  It follows that back donation from FeII 
to the TIM ligand in [Fe(TIM)(CH3CN)2]2+ is greater than back donation from FeII to the anionic 
porphyrin in an [FeII(heme)] complex. The formation constants, KNO and KCO, are expected to be 
lower for the [FeII(TIM)(CH3CN)]2+ species than those for the related [FeII(heme)] species 
because stronger metal donation to the TIM ligand diminishes metal donation to the axial NO or 
CO ligand in the [FeII(TIM)(CH3CN)]2+  complex.  
Given that, like the TIM ligand, quadridentate ligands based on thioalkylated 
isothiosemicarbazides also resemble biological complexes, Stavrov and Arion et al.116 
synthesized iron mononitrosyl complexes [Fe(HL)NO]NO3 where H3L = 2,4-pentanedione bis(S-
methylisothiosemicarbazone) and [Fe(R2Q)NO], where R = CH3, C2H5, n-C3H7, and n-C4H9.  
Figure 2.32 depicts [Fe(HL)NO]NO3, while Figure 2.33 illustrates [Fe(R2Q)NO].  The 
complexes were characterized by 1H NMR, IR, Mossbauer, and electronic absorption 
spectroscopies.  X-ray crystal structures, obtained for the square-pyramidal complexes 
[Fe(HL)NO]NO3 and [Fe(R2Q)NO], where R = n-C3H7, are shown in Figures 2.34 and 2.35 
respectively. Both complexes exhibit a nearly linear NO group, consistent with [FeIINO+] 
formalisms. 
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Figure 2.32 − [Fe(HL)(NO)]NO3  
HL3 = 2,4-pentanedione bis(S-methylisothiosemicarbazone (Reprinted from Inorg. Chim. Acta, 202, Gerbeleu, N. 
V., Arion, V. B., Yu, A., Zavodnik, V. E., Stavrov, S. S., Turta, K. I., Gradinau, D. I., Birca, M. S., Pasynskii, A. A., 
Ellert, D., 173-181, Copyright 1992, with permission from Elsevier. 114) 
 
 
                                    
 
Figure 2.33 − [Fe(R2Q)(NO)] 
H3R2Q = nitromalondialdehyde bis(S-alkylisothiosemicarbazone (Reprinted from Inorg. Chim. Acta, 202, Gerbeleu, 
N. V., Arion, V. B., Yu, A., Zavodnik, V. E., Stavrov, S. S., Turta, K. I., Gradinau, D. I., Birca, M. S., Pasynskii, A. 
A., Ellert, D., 173-181, Copyright 1992, with permission from Elsevier. 114) 
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Figure 2.34 − [Fe(HL)(NO)]+  
HL3 = pentandione bis(S-methylisothiosemicarbazone (Reprinted from Inorg. Chim. Acta, 202, Gerbeleu, N. V., 
Arion, V. B., Yu, A., Zavodnik, V. E., Stavrov, S. S., Turta, K. I., Gradinau, D. I., Birca, M. S., Pasynskii, A. A., 
Ellert, D., 173-181, Copyright 1992, with permission from Elsevier. 114) 
 
 
 
 
Figure 2.35 − [Fe(R2Q)(NO)]  
H3R2Q = nitromalondialdehyde bis(S-propyl-isothiosemicarbazone (Reprinted from Inorg. Chim. Acta, 202, 
Gerbeleu, N. V., Arion, V. B., Yu, A., Zavodnik, V. E., Stavrov, S. S., Turta, K. I., Gradinau, D. I., Birca, M. S., 
Pasynskii, A. A., Ellert, D., 173-181, Copyright 1992, with permission from Elsevier. 114) 
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Self-consistent charge molecular orbital calculations (SCC-MO) for the {FeNO}6 complexes 
[Fe(H3L)NO]NO3 and [Fe(R2Q)NO] indicate that the geometry of NO coordination, along with 
v NO, is largely determined by the total number of metal ion d-electrons  and the π-electrons of 
NO. When n < 6 the NO group should be linear with IR stretching frequencies similar to that of 
the neutral molecule.  When n > 6  a bent nitrosyl is predicted.  Infrared stretching frequencies,  
when n > 6,  should be closer to the values expected for NO−. Based upon their theoretical and 
experimental findings the authors conclude that the electronic structure of the quadridentate 
ligands (having more heteroatoms than TIM) approximates that observed in porphyrins. 
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 2.4. DINITROSYL COMPLEXES 
Equimolar amounts of Fe(NO)2(CO)PPh3 and tetracyanoethane (TCNE) in diethyl ether yield 
Fe(NO)2PPh3(η2-TCNE)117 with loss of CO, within 1-2 h at ambient temperature.  Figure 2.36 
shows that Fe(NO)2PPh3(η2-TCNE) exhibits two linear MNO groups. Upon coordination the 
olefinic carbon atoms of TCNE lose planarity as the π bond lengthens. The carbon atoms gain 
sp3 character as the result of backdonation to the π∗ antibonding orbitals from the metal d 
orbitals.  Accordingly the 13C NMR signals for the olefinic carbons shift upfield upon 
coordination. Back-donation from filled metal d orbitals to vacant TCNE π* orbitals also 
decreases the TCNE CN stretching frequency and reduces back donation from the metal to NO. 
As a result IR signals for the nitrosyl groups in Fe(NO)2PPh3(η2-TCNE) occur at higher 
frequency ( v NO = 1834 cm-1 and 1790 cm-1) than those of the precursor, Fe(NO)2(CO)PPh3 ( v NO 
= 1766 cm-1 and 1718 cm-1). The relatively rapid carbonyl replacement is explained by a free 
radical mechanism that invokes a 17 electron intermediate (Figure 2.37). 
 
 
 
Figure 2.36 − ORTEP Diagram of Fe(NO)2PPh3(η2-TCNE) and Solvent Molecule.   
Selected bond lengths and bond angles:  Re-P = 2.296(2) Å; Fe-N = 1.657(6) and 1.665(6) Å; Fe-C1/FeC2 = 
2.029(7)/2.101(6) Å; C1-C2 = 1.473(9) Å; N1-Fe-N2 = 118.9º; Fe-N1-O1 = 178.0(5)º; Fe-N2-O2 = 165.8(5)º.  
(Reprinted with permission from Organometallics, 1994, 13, 4686-4688. Copyright 1994 American Chemical 
Society. 115) 
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Figure 2.37 − Suggested Reaction Pathway 
An Electron Transfer Autocatalysis Mechanism (Reprinted with permission from Organometallics, 1994, 13, 4686-
4688.  Copyright 1994 American Chemical Society. 115) 
 
Blackwell118 and co-workers reported the electrochemical and spectroscopic investigation 
of the interconversion of 18 electron [FeXL(NO)2] complexes and 17 electron [FeL2(NO)2] 
complexes where L = PEt3, PPh3, or dppe and where X = Cl or I.  These complexes provide the 
basis for a proposed redox-based scheme in which one electron reduction activates the 17 
electron [FeL2(NO)2] complexes toward substitution by better π acceptors while one electron 
oxidation activates 18 electron [FeL2(NO)2] complexes toward substitution by σ donors (Figure 
2.38).   
 
Figure 2.38 − Interconversion of 18 e- [FeXL(NO)2] and 17 e- [FeL2(NO)] 
(J. Chem. Soc. Dalton Trans., 1996, 3491-3502 – Reproduced by permission of The Royal Society of Chemistry) 
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 A series of iron dinitrosyl complexes of the form Fe(NO2)(PR3)(η2-TCNE)119 where PR3 
= P(OCH3), P(n-Bu)3, PMe2Ph, and PEt2Ph  forms within 3 hours upon reaction of the respective 
Fe(NO2)(PR3)(CO) complex with TCNE in diethyl ether.  The products, which are soluble in 
CH2Cl2, THF, (CH3)2CO, CH3CN, and MeOH decompose in solution after a few days in a 
disproportionation reaction, similar to that shown in Figure 2.38, in which Fe(NO)2(PPh3)2+ 
converts to Fe(NO)2(PPh3)2.  The rapid formation of the TCNE product is believed to proceed 
through the same sort of 17 electron intermediate formed in the electron transfer autocatalysis 
which mechanism described Figure 2.37.   
       A decrease in NO stretching frequency upon addition of the phosphorus donor to 
Fe(NO)2(CO)2 arises from increased electron density at the iron center and subsequent increased 
backbonding to vacant π∗  orbitals of the nitrosyl from filled iron d orbitals. This shift in νNO is 
reversed upon addition of TCNE as a result of efficient back donation from the iron d orbitals to 
the π* orbitals of TCNE. The CN group of coordinated TCNE exhibits a corresponding decrease 
in stretching frequency as well. A positive shift in reduction potentials of the TCNE complexes 
compared to the carbonyl precursor supports the existence of strong metal backbonding to empty 
π* orbitals of TCNE.  The X-ray crystal structure of Fe(NO)2P(OMe)3(η2-TCNE), shown in 
Figure 2.39, exhibits linear NO groups in an attracto conformation. NMR studies reveal 
restricted rotation about the Fe-TCNE π  bond,  which reflects enhanced back-donation from 
metal d orbitals to the π* orbitals of the alkene.  As illustrated in the second view of the x-ray 
crystal structure shown in Figure 2.40, there may be additional restrictive π orbital interactions 
between the NO and CN π systems due to alignment of the CN groups immediately above the 
NO groups. 
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Figure 2.39 − The Molecular Structure of Fe(NO)2P(OMe)3(η2-TCNE) 
Anisotropic thermal ellipsoids are shown at 30%.  (Reprinted from J.  Organomet. Chem., 558, Hőrsken, Arne, 
Zheng, Guodong, Stradiotto, Mark., McCrory, Christopher. T. C., Lijuan, Li, 1-9, Copyright 1998, with permission 
from Elsevier. 117)   
 
 
 
 
 
 
Figure 2.40 − The Molecular Structure of Fe(NO)2P(OMe)3(η2-TCNE) 
showing 50% thermal ellipsoids, viewed from the centroid of the C(1)-C(2) bond to the iron atom.  The OCH3 
groups have been omitted for clarity.   (Reprinted from J.  Organomet. Chem., 558, Hőrsken, Arne, Zheng, 
Guodong, Stradiotto, Mark., McCrory, Christopher. T. C., Lijuan, Li, 1-9, Copyright 1998, with permission from 
Elsevier. 117)   
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 The first X-ray crystal structure of a non-heme-iron dinitrosyl complex of the g = 2.03 
family that bears an imidazole ligand, Fe(NO)2(1-methylimidazole)2,120 formed from the rapid 
reaction of Fe(NO)2(CO)2 with an excess of 1-methylimidazole in diethyl ether, is shown in 
Figure 2.41.  The rapid reaction again suggests the presence of a 17 electron iron radical 
intermediate that facilitates carbonyl substitution by 1-methylimidazole.  EPR studies and 
Mossbauer spectroscopy support  the existence of 17-electron intermediate [Fe(NO)2(1-MeIm)2]+ 
whose EPR signal disappears upon formation of the green crystal [Fe(NO)2(1-MeIM)2].  The 
linear nitrosyl groups (167.5(3)° and 170.1(3)°) are symmetrically tilted with the two oxygen 
atoms oriented toward each other in an attracto conformation. The nitrosyl stretching frequencies 
shifted from 1810 and 1767 cm-1 for Fe(NO)2(CO)2 to 1673 and 1616 cm-1 upon addition of the 
1-MeIm ligands which act as good σ donors and decrease the NO stretching frequencies as 
rationalized by molecular orbital calculations.  
 
 
 
Figure 2.41 − X-ray Structure of Fe(NO)2(I-MeIm)2
showing the atomic numbering scheme.  Anisotropic thermal displacement ellipsoids are shown at the 50% 
probability level.  Selected bond distances and angles:  Fe-Ni/Fe-N2 = 1.648(3)/1.650(3) Å;Fe-N3/Fe-N5 = 
2.044(3)/2.048(3) Å; N1-O1/N2-O2 = 1.189(3)/1.188(4)  Å; N1-Fe-N2 = 116.57(14)º; N3-Fe-N5 = 91.20(11)º; N1-
Fe-N3/N1-Fe-N5 = 111.28(13)/112.76(12)º; N2-Fe-N3/N2-Fe-N5 = 114.43(13)/107.78(13)º. (Reprinted with 
permission from J. Am. Chem. Soc., 1999, 121, 10217-10218. Copyright 1999 American Chemical Society. 118) 
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 2.5. BIMETALLIC NITROSYLS 
Lower oxidation state bimetallic Fe and Ni organometallic complexes are of interest as models 
for Fe/Ni/S hydrogenase enzymes.  Many syntheses have been directed toward hydrogenase 
active site modeling.  The dinitrosyl diiron complex [Fe2(Et-HPTB)(O2CPh)(NO)2](BF4)2121 (Et-
HPTB = N,N,N′,N′-tetrakis(N-ethyl-2-benzimidazolyl-methyl)-2-hydroxy-1,3-diaminopropane) 
formed upon addition of NO to [Fe2(Et-HPTB)(O2CPh)](BF4)2. The crystal structure (Figure 
2.42) shows equivalent and slightly bent (166.6(7) and 168.3(7)°) Fe-NO groups. The {FeNO}7 
complex was characterized by magnetic susceptibility, Mossbauer, optical, and IR 
spectroscopies. Extended Huckel molecular orbital calculations on a model complex, 
[Fe2(NO)2(NH3)6(OH)(O2CH)]2+, indicate that the 167° Fe-N-O bond angle is dictated by the Fe-
N π-bonding orbitals rather than by the π-antibonding HOMO.   
 
 
Figure 2.42 − ORTEP Representation of the Cation [Fe2(Et-HPTB)(O2CPh)(NO)2](BF4)2
(40% probability ellipsoids) with hydrogen atoms removed for clarity (Reprinted with permission from Inorg. 
Chem., 1996, 35, 6892-6898. Copyright 1996 American Chemical Society. 119) 
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 Knox122 and co-workers prepared two di-iron nitrosyl complexes by using Fe2(CO)9 to 
induce homolytic cleavage of the X-NO bond of nitrosoamines. Specifically, R2NNO (R = 
methyl or ethyl) reacted with Fe2(CO)6 to form (OC)4Fe(μ-CNR2)Fe(CO)2NO.  A crystal 
structure of the ethyl derivative exhibited a linear nitrosyl group.  Both complexes were 
characterized by IR spectroscopy.  In the same study Fe(CO)2(NO)2 was synthesized from the 
reaction between ethyl nitrite and Fe2(CO)9 as well as from the reaction between silver nitrite 
and Fe(CO)4I2. 
Glidewell and co-workers123 formed [Fe(SMe)2(NO)4] by direct incorporation of the SMe 
fragment of methionine. In the presence of iron(II)sulfate and sodium nitrite, methionine 
produced [Fe2(SMe2)(NO)4].   The product was characterized by IR, 1H NMR, 13C NMR, 15N 
NMR, spectroscopies as well as by mass spectrometry. Ethionine, methionine ethyl ester, and S-
methylcysteine reacted similarly. Control experiments using iron(II)chloride instead of iron(II) 
sulfate confirmed that the sulfur in the product originated from the methionine rather than from 
reduction of sulfate.  This methodology124 was extended to form similar dinuclear complexes as 
well as tetranuclear [Fe4S3(NO)7]− from iron(II), nitrite and the cysteine and penicillamine 
derivatives shown in Figure 2.43  Thiols 1-6, 12 and 13 only yielded Na[Fe4S3(NO)7] under 
autoclave conditions; however, at reflux under nitrogen, thiols 2, 4, 6, 12 and 13 formed 
dinuclear complexes [Fe2(SR)2(NO)4] in addition to [Fe4S3(NO)7]−.  Lanthionine formed the 
tetranuclear complex only in the presence of ascorbate.  In contrast to 12 and 13, S-nitroso-N-
acetylpenicillamine (SNAP) 14 acted as an NO source rather than as a sulfur source. 
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Figure 2.43 − Methionine, Cysteine, and Penicillamine Derivatives 
(Reprinted from Polyhedron, 11, Anthony R. Butler, Christopher Glidewell* and Sheila M. Glidewell, “Formation 
of Bismethanthiolatobis(Dinitrosyliron) [Fe2(SMe)2(NO)4] By Capture of Methanethiol Groups From Methionine 
and Its Derivatives in Reactions With Iron(II) And Nitrite”, 591-596, 1992, with permission form Elsevier. 122) 
 
62 
 Osterloh and co-workers125 synthesized the heterobinuclear [Ni(μ-SR)2Fe(NO)2] complex 
via the reaction depicted in Figure 2.44.  Two carbonyls of Fe(CO)2(NO)2 are displaced by a 
square planar N2S2 complex of NiII.  The crystal structure is shown in figure 2.45. The small Ni-
Fe distance of 279.7(1) pm, compared to that for the binuclear complex of the active center of 
NiFe Hydrogenase at 290 pm is partially explained by the low coordination number of the iron 
center.  While infrared data does not mimic the absorption pattern for NiFe hydrogenase, the 
authors do not rule out the possibility that a nitrosyl ligand is at the active center of NiFe 
hydrogenase because ligand effects may cause the variation.  
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Figure 2.44 − Formation of Ni(μ-SR)2Fe(NO)2
(J. Chem. Soc., Chem. Commun. 1997,  979-980  reproduced by permission of the Royal Society of Chemistry 123) 
 
 
Figure 2.45 − Molecular Structure of Ni(μSR)2Fe(NO)2
Molecular Structure of Ni(μSR)2Fe(NO)2 with atom labeling scheme:  Ni(μSR)2Fe(NO)2 exhibits crystallographic 
mirror symmetry; H atoms have been omitted. (J. Chem. Soc. Chem. Commun. 1997, 979-980 – Reproduced by 
permission of The Royal Society of Chemistry. 123) 
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 Liaw and co-workers126 prepared analogues of Osterloh’s N2S2 complex. Coordination of 
other S donating ligands to [Fe(NO)2(CO)] and [Fe(NO)2] generated the series of monomeric and 
homodimetallic derivatives of the Fe(NO)2 fragments shown in figure Figure 2.48.  The crystal 
structure of the dinitrosyl iron complex [Fe(NO)2[(PhSe)2]−, formally Fe(-I) with two NO+ 
ligands, is displayed in figure 2.46. The [Fe(NO)2[(PhSe)2]− complex is a precursor to the neutral 
heterobimetallic [(ON)Ni(μ-S(CH2)S(CH2)2S)Fe(NO)2] which exhibits linear nitrosyls as shown 
in Figure 2.47.   
 
 
 
 
 
 
 
 
Figure 2.46 − Labeling Scheme for [Fe(NO)2(SePh)2]− 
with thermal ellipsoids drawn at the 50% probability level.  Fe-Se, 2.395(1); Fe-N(1), 1.669(4); N(1)-O(1), 1.162(5).  
Se-Fe-Se(a), 114.08(5); Se-Fe-N(1), 107.88(13); Se-Fe-N(1a), 105.06(13); N(1)-Fe-N(1a), 117.20(19); Fe-N(1)-
O(1), 169.2(4).  (Reprinted with permission from Inorg. Chem., 2000, 39, 480-484.  Copyright 2000 American 
Chemical Society. 124) 
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igure 2.47 − [(ON)Ni(μ−S(CH2)2S(CH2)2S)Fe(NO)2] 
abeling scheme for [(ON)Ni(μ-S(CH2)2S(CH2)2S)Fe(NO)2] with thermal ellipsoids drawn at the 50% probability 
, 1.670(2); Fe-N(2), 1.674(3); N(1)-O(1), 1.163(3); N(2)-
 
 
F
L
level.  Fe-S(1), 2.2907(9); Fe-S(3), 2.3039(9); Fe-N(1)
,O(2), 1.159(3); Ni-S(3), 2.2931(9); Ni-N(3)  1.644(2); N(3)-O(2), 1.119(3); Ni-Fe, 2.8001(6). S(1)-Fe-S(3), 
103.73(3); S(1)-Fe-N(1), 114.88(9); S(1)-Fe-N(2), 106.03(9); N(1)-Fe-N(2), 115.06(12); S(1)-Ni-S(2), 91.67(3); 
S(1)-Ni-S(3), 103.94(3); S(1)-Ni-N(3), 120.53(10); S(2)-Ni-S(3), 92.31(4); S(2)-Ni-N(3), 126.69(9); S(3)-Ni-N(3), 
115.83(10); Fe-S(1)-Ni, 75.28(3); Fe-S(3)-Ni, 75.05(3); Fe-N(1)-O(1), 1.66.21(23); Fe-N(2)-O(2), 167.3(3); Ni-
N(3)-O(3), 175.1(3). (Reprinted with permission from Inorg. Chem., 2000, 39, 480-484. Copyright 2000 American 
Chemical Society. 124) 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
  
igure 2.48 − Selected Structure and Infrared Data for Dichalcogenide {Fe(NO)2}9,10
ased on Enemark−Feltham Notation (Reprinted with permission from Inorg. Chem., 2000, 39, 480-484. Copyright 
000 American Chemical Society. 124
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 Nitrosprussides, [Fe(CN)5NO]2− are of interest because of their unusual magnetic and 
127,128
129
54 13 15
130
s131 reported the X-ray crystal structure and magnetic properties of 
polyme
II
II
Figure 2.49 − Perspective View of [Cu2(oxpn)Fe(CN)5(NO)]
(Reprinted with permission from Inorg. Chem., 1995, 34, 225 2257. Copyright 1995, American Chemical Society. 
125
electronic behavior and because of their inhibitory effect on superoxide dismutase.  Two 
excited metastable states for sodium nitrosprusside, [Na2Fe(CN)5NO], have been observed; 
several of their vibrational modes have been assigned.   The wavenumbers and isotopic shifts 
for majority of the 33 vibrational modes of normal and Fe C and N(O) enriched sodium 
nitrosprusside dihydrate have also been obtained by FTIR and NIR Raman spectrscopies.   
Heterobinuclear complexes, in which the nitrosprusside ion is bridged via cyanide to other metal 
sites, have been prepared.   
Tang and co-worker
ric [Cu2(oxpn)Fe(CN)5(NO)]n (oxpn = dianion of N, N′ - bis(3-aminopropyl)oxamide) 
(Figure 2.49).  The authors suggest that a very weak antiferromagnetic exchange in this trans-
oxamidato-bridged compound, compared with that in other trans-oxamidato bridged compounds, 
may be due to the trigonal bipyramidal character of the Cu  ion, which renders the two magnetic 
orbitals in the Cu  dinuclear unit unable to interact from each side of the oxamidate bridge.
 
n
5-
) 
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 Shyu and co-workers132 prepared the discrete double complex 
py[Ni(b )3][Fe(CN)5(NO)]•3H2O shown in Figure 2.50 and the dimensional polymeric complex 
[Ni(en)2Fe(CN)5(NO)]•H2O, shown in Figure 2.51.  Both nitrosyl groups are nearly linear with 
v NO = 1911 and 1933 cm  respectively.  The outer-sphere bpy complex exhibits classical 
magnetic behavior, while the ethylenediamine complex exhibits a very weak 
antiferromagnetic interaction between the two adjacent Ni(II) ions, possibly through the 
[Fe(CN)
-1
para
2−
 
 
Figure 2 0 − ORTEP Stereoview of [Ni(bpy)3][Fe(CN)5(NO)]  
Shown without H2O, 30% probability thermal ellipsoids.  (Reprinted from Inorg. Chim. Acta, 258, Huey Lih Shyu, 
Ho Hsiang Wei, Yu Wang, “Preparation, characterization and crystal structure of [Ni(bpy)3][Fe(CN)5(NO)]•3H2O 
, 81-86, Copyright 1997, with permission from 
5(NO)]  group. 
 
 
 
.5
and one dimensional cyanobridged [Ni(en)2Fe(CN)5(NO)]•H2O”
Elsevier. 126) 
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Figure 2.51 − ORTEP Stereoview of [Ni(en)2Fe(CN)5(CO)] 
Shown without H2O; 30% probability thermal ellipsoids.  (Reprinted from Inorg. Chim. Acta, 258, Huey Lih Shyu, 
Ho Hsiang Wei, Yu Wang, “Preparation, characterization and crystal structure of [Ni(bpy)3][Fe(CN)5(NO)] 3H2O 
and one dimensional cyanobridged [Ni(en)2Fe(CN)5(NO)]•H2O”, 81-86, Copyright 1997, with permission from 
Elsevier. 126) 
 
  To investigate the correlation between magnetic properties and structure in nitroprusside 
bridged complexes, Liao133 prepared a new one-dimensional chain complex 
[Cu(en)2Fe(CN)5(NO)], obtained its crystal structure, and determined its magnetic properties.  
The crystal structure shown in Figure 2.52 consists of alternating Cu(en)2+ and [Fe(CN)5(NO)]2− 
fragments connected in cis configuration by two cyanide ligands of the    [Fe(CN)5(NO)]2−  
fragment.  The bridging cyanides are bent; longer axial distances Cu-N are attributed to the 
Jahn−Teller effect for the d9 configuration of this distorted octahedral CuII ion. Magnetic 
measurements reveal a drop in the effective magnetic moment (μeff) at low temperatures, which 
indicates a weak antiferromagnetic coupling between copper ions.  The weak interaction is 
rationalized by considering the large nearest Cu-Cu distance and the weakened Jahn−Teller 
distorted axial Cu-N contacts. The calculated J value for [Cu(en)2Fe(CN)5(NO)] is over twice 
that for [Ni(en)2Fe(CN)5(NO)]. The authors propose that the lower energy of the magnetically 
active 3d orbitals of  Cu(II) compared to those of nickel(II) moves the 3d orbitals of Cu(II) closer 
in energy to the symmetry-adapted-highest occupied molecular orbitals of [Fe(CN)5(NO)]2-. 
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Figure 2.52 −  ORTEP Drawing of Cu(en)2Fe(CN)5(NO) 
Shows thermal ellipsoids at the 30% probability level. (Reprinted From Aust. J. Chem., 51, Hui-Zhong Kou, Hong-
Mei Wang, Dai-Zheng Liao, Peng Cheng, Zong-Hui Jiang, Shi-Ping Yan, Xiao-Ying Huang and Geng-Lin Wang, 
“A New One-Dimensional Bimetallic Complex: Cu(en)2Fe(CN)5(NO).  Synthesis, Crystal Structure and Magnetic 
Behavior, 661-665, Copyright 1998, with permission from CSIRO publishing, 129).  
 
 
 
Liao127 and co-workers also synthesized relatively insoluble 
[Cu(bpy)][Fe(CN)5(NO)]•2H2O which upon dissolving in a hot acetyl acetone and pyridine 
mixture formed the mixed metal complex [Cu(acac)(bpy)](py)]2[Fe(CN)5(NO)] for which the 
crystal structure shown in Figure 2.53 was obtained. The crystal structure comprises two 
[Cu(acac)(bpy)](py)]+ cations and one [Fe(CN)5(NO)]2− anion.  The nitrosyl ligand, assigned as 
NO+, is indistinguishable from the CN ligand trans to it. The iron center is considered FeII as it is 
in the sodium nitrosprusside analogue.  The authors propose that the weak magnetic interactions 
detected by EPR and magnetic studies may be attributed to π-stacking contacts between 
coordinated bpy ligands.   
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Figure 2.53 − ORTEP Drawing of [Cu(acac)(bpy)(py)]2[Fe(CN)5(NO)] 
Shows 30% probability ellipsoids and the atomic labeling scheme. (Reprinted from Acta Chem. Scandinavica, 53, 
1999, Hui-Zhong Kou, En-Qing Goa, Dai-Zheng Liao, Peng Cheng, Zong-Hui Jian, Shi-Ping Yan, Geng-Lin Wang, 
Zin-Kan Yao, Hong-Gen Wang and J. P. Tuchagues, “A new Copper(II) Iron(II) Complex 
[Cu(acac)(bpy)(py)]2[Fe(CN)5(NO)] based on Nitroprusside:  Synthesis, Structure and Spectroscopic Studies”, 542-
546, with permission form Blackwell Publishing. Ltd.) 
 
Smekal128 and co-workers obtained the crystal structure of the dimeric 
[Cu(H2NCH2CH(NH2)CH3)2Fe(CN)5NO]•2H2O, which is analogous to the polymeric 
[Cu(en)Fe(CN)5NO].  The authors propose that methyl groups on the propane-1,2-diamine 
interfere with polymer formation.  The crystal structure, presented in figure 2.54 illustrates that 
the copper(II) ion is coordinated by five nitrogen atoms, four from two propane-1,2-diamine 
ligands and one from a bridging cyanide ligand in a distorted tetragonal pyramid. The linear 
nitrosyl group in the distorted octahedrally coordinated [Fe(CN)5NO]2− fragment is cis to the 
bridging cyanide group.  In the same study four other new bimetallic complexes were prepared 
and characterized by IR and UV-vis spectroscopies in addition to magnetic measurements.  The  
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Figure 2.54 − Molecular Structure of [Cu(1,2-pn)2Fe(CN)5NO]•H2O 
Shown with the atom numbering scheme.  Hydrogen atoms are omitted for the sake of clarity. (Reprinted from Aust. 
J. Chem., 53, Zdenék Smékal*, Zdenék Trávniček, Jarmir Marek and Milan Nádvornik, “Cyano-Bridged Bimetallic 
Complexes of Copper(II) with Nitroprusside.  Crystal Structure of [Cu(H2NCH2CH(NH2)CH3)2Fe(CN)5NO]•H2O”, 
225-228, Copyright 2000, with permission form CSIRO Publishing,  (131)) 
 
four other new complexes, [Cu(L)Fe(CN)5NO]•xH2O (L = tmen (N,N,N′,N′ - tetramethylethane-
1,2-diamine), x = 0.5; L = trimeen (N,N,N′-trimethylethane-1,2-diamine), x = 1; L = dien (N-(2-
aminoethyl)ethane-1,2-diamine), x = 0; L = medpt (N-(3-aminopropyl)-N-methylpropane-1,3-
diamine), x = 2) were obtained from the reaction between Cu(ClO4)2•6H2O or CuCl2•2H2O, 
Na2[Fe(CN)5NO] •2H2O, and the amine in water.  
To clarify the correlation between structure and magnetic properties of dinuclear 
complexes with the [Fe(CN)5(NO)]2- anion, Mitra134 and co-workers prepared and characterized 
two new cyano-bridged heterometallic complexes [Cu(dmen)2Fe(CN)5(NO)] (dmen = 2-
dimethylaminoethylamime) and [Cu(dmpn)2Fe(CN)5(NO)]  (dmpn = 1-dimethylamino-2-
propylamine).  In both structures the distorted octahedral FeII center connects to the distorted 
square pyramidal CuII ion through a bent cyano bridge. In agreement with molecular orbital 
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 theory the NO+ is linear. There is no magnetic interaction between CuII and FeII in either 
complex. 
To verify the existence of an interaction  between two metallic centers through a different 
metal center Gerbase et al.135 prepared the formally d10 Co(−I) and Fe(−II) complexes 
[(dppf)(CoNO)2][SbF6] (dppf = 1,1′ -bis(diphenylphosphino)ferrocene), [(dppf)Fe(NO)2] as well 
as [(dppf)(FeCO)3].  The crystal structure of [(dppf)(CoNO)2][SbF6] shown in figure 2.55 reveals 
two linear nitrosyl groups which absorb at 1850 and at 1789 cm-1.  The dppf chelates to the 
cobalt nitrosyl  moiety in a distorted tetrahedral fashion. The complex may be considered 
formally Co(−I) with two NO+ ligands. Mossbauer data revealed a weak interaction between the 
two metal atoms through the dppf ligand. Mossbauer parameters also show that electronic effects 
of powerful π acceptors, such as CO and NO+ are very different from those observed for σ and π 
donors.  For the halide series, the distortion of the ferrocenyl moiety had been attributed to 
coordination geometry of the metal rather than to the nature if the ligands.  For example, in 
Mossbauer studies of a series of dppf metal halide and carbonyl complexes, Houlton et al.136   
reported that tetrahedral complexes produce the highest IS (0.55-0.58 mm s-1) and the highest QS 
(2.29-2.36 mm s-1), octahedral complexes (dppfM(CO)4, M = Pd, Pt, Cd) had intermediate IS 
(0.52-0.54 mm s-1) and QS (2.23-2.27 mm s-1) values, and that square planar complexes 
(dppfMCl2, M = Pd, Pt, Cd) had the lowest IS (0.50-0.51 mm s-1) and QS (2.14-2.29 mm s-1) 
parameters.  Thus it was concluded that the geometry of the metal, rather than the ligand 
electronic character that influences the hyperfine interactions of the ferrocenyl iron atom.  
However, the Mossbauer parameters of ferrocenyl iron in the tetrahedral complexes 
dppfFe(NO)2 (IS = 0.52 mm s-1, QS = 2.34 mm s-1) and [dppfCo(NO)2][SbF6] (IS = 0.52 mm s-1, 
QS = 2.30 mm s-1) do not fit the coordination geometry-based trend suggested by Houlton et 
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 al.136  On the contrary, in addition to the steric component, there is an electronic contribution to 
the effect of the MLn moiety on the Mossbauer parameters of the ferrocenyl Fe atom. 
Electrochemical studies indicate that, in solution, MLn coordination hinders iron dppf oxidation 
and can change the oxidation mechanism.    
 
Figure 2.55 − ORTEP Plot of [dppfCo(NO)2][SbF6] Cation 
Displacement of ellipsoids at the 50% level; H atoms omitted for clarity. (Reprinted from Inorg. Chim. Acta, 266, 
Annelise E. Gerbase, Eduardo, J. S. Vichi, Edison Stein, Livio Amaral, Adalberto Vasquez, Manfredo Hörner, 
Cäcilia Maichle-Mössmer, “Preparation, characterization and electrochemical studies of 1,1-bis(diphenylphosphine) 
ferrocene (dppf) derivatives. Crystal structure of [dppfCo(NO)2][SbF6]”, 19-27, Copyright 1997, by permission from 
Elsevier. 127)   
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 2.6. CLUSTERS 
Metal nitrosyl clusters are of interest to chemists in various branches of chemistry For example, 
organometallic chemists investigate metal nitrosyl clusters for  catalytic applications.137  
Theoretical chemists are interested studying metal nitrosyl cluster frameworks. And biochemists 
are interested in clusters such as Roussin’s salts and their which have potential applications to 
photodynamic therapy. 138-140 
Many derivatives 139-144 of Roussin’s red salt, Na2[Fe2S2(NO)4] and Roussin’s black salt 
NH4[Fe5S4(NO)7] have been reported since Roussin’s salts were discovered in 1858;145 however, 
until Dance and coworkers reported the synthesis of [Fe5S4(NO)8]− and [Fe7S6(NO)10]−,146 the 
only other known nitrosyl containing sulfide clusters were [Fe4S4(NO)4]z (z = 0, -1)147,148 and 
[Fe6S6(NO)6]2−.149 The structures of [Fe2S2(NO)4]2−, [Fe5S4(NO)8]−, [Fe4S4(NO)4]z,  
[Fe6S6(NO)6]2−, proposed on the basis of density functional calculations, are  illustrated in Figure 
2.56.   
 
 
Figure 2.56 − [Fe2S2(NO)4]2-,  [Fe4S3(NO)7]z, [Fe4S4(NO)4]z,  z = 0, -1, and [Fe6S6(NO)6]2- 
[Fe2S2(NO)4]2- (1), [Fe4S3(NO)7]z (2),  [Fe4S4(NO)4]z (3), z = 0, -1, and [Fe6S6(NO)6]2- (4) (Chem. Commun., 2000, 
947-948 - Reproduced by permission of the Royal Society of Chemistry. 142) 
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  Relatively rapid formation of [Fe5S4(NO)8]− and [Fe7S6(NO)10]− occurs under negative ion 
electrospray mass spectrometry conditions from a solution of Na2[Fe2S2(NO)4] in methanol or in 
acetonitrile. The lack of observable intermediates, suggests a facile associative mechanism which 
involves collisions of [Fe2S2(NO)4]2− complexes, followed by simple connectivity changes 
between the starting materials and the products.   
Scott and Holm studied the following tetranuclear iron sulfur clusters with linear NO+ 
nitrosyl ligands:  [Fe4S3(NO)7]−, [Fe4S4(NO)4], [Fe4S4(NO)4]−, [Fe4S3(NO)4(PPh3)3], 
[Fe4S3(NO)4(PPh3)3]+, [Fe6S6(NO)6]2− 149  Crystal structures were obtained for  
[Fe4S3(NO)4(PPh3)3], [Fe4S3(NO)4(PPh3)3]+, and [Fe6S6(NO)6]2−. The [Fe6S6(NO)6]2−  complex 
was isolated as [Fe(dmf)6][Fe6S6(NO)6] and as [Et4N]2[Fe6S6(NO)6]. The cluster [Fe6S6(NO)6]2− 
whose crystal structure is displayed in figure 2.57 is the first example of a structure, for 
Fe(NO)(S)L, systems with a bridging ligand with  L ≠ RS−, RO− or halide.  The X-ray crystal 
structures of [Fe4S3(NO)4(PPh3)3] and [Fe4S3(NO)4(PPh3)3]+ shown in figures 2.58 and 2.59 
exhibit a cuboidal Fe4S3 core.  Holm150 later extended his study of [Fe4S3(NO)4(PR3)3] clusters to 
include phosphines of larger cone angle and higher basicity,  where R = Et, Pri, and Cy and 
found that the cuboidal core is maintained.  
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 Figure 2.57 − Crystal Structure of [Fe6S6(NO)6]2− as its Et4N+ Salt 
Shows 30% probability ellipsoids; Selected interatomic distances [pm] and angles [º]: Fe(1)-Fe(2) 266.3(2).  Fe(1)-
Fe(3)´ 265.6(2).  Fe(2)-Fe(3) 265.9(2). mean Fe-S 222.1(5). mean Fe-N 166(1). Mean Fe-N-O 176(1); within the 
Fe3S3 cyclohexane-type ring mean values are S-Fe-S 113.2(9), Fe-S-Fe 111.9(8): within the Fe2S2 rhombuses 
mean values are S-Fe-S 106.3(2) and Fe-S-Fe 73.6(2). Primed and unprimed atoms are related by an inversion 
center. (Reprinted with permission from Angew. Chem. Int. Ed., Engl., 1993, 32, 564-566. Copyright 1993, John 
Wiley & Sons.) 
 
 
Figure 2.58 − The Structure of [Fe4S3(NO)4(PPh3)3] 
Phenyl groups omitted, 30% probability ellipsoids.  Selected interatomic distances [pm] and angles [º]:  Fe(1)-Fe(2) 
257.1(2), Fe(1)-Fe(3) 261.4(2), Fe(1)-Fe(4) 262.8(2), Fe(2)-Fe(3) 277.1(2), Fe(2)-Fe(4) 278.0(2), Fe(3)-Fe(4) 
267.8(2), Fe(1)-S 224.3(17), Feb-S 221.4(7), Fe-P 224.8(5), S-Fe(1)-S 105.5(16), S-Fe(1)-N(1) 113.2(7), Fe(1)-S-
Feb 71.5(7), Feb-S-Feb 76.6(18), S-Feb-S 107.5(14), S-Feb-N 124(6), S-Feb-P 95.7(20), N-Feb-P 98.1(5). Fe(1)-
N(1)-O(1) 177.9(7), Feb-N-O 177.0(6). Except for the unique angle, data involving P, S, and N atoms are mean 
values under idealized trigonal symmetry (Feb = Fe(2)-Fe(4)). (Reprinted with permission from Angew. Chem. Int. 
Ed. Engl., 1993, 32, 564-566.  Copyright 1993 John Wiley & Sons, Inc.)   
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Figure 2.59 − Structure of [Fe4S3(NO)4(PPh3)3]+  
From the solvated [Fe4S3(NO)4(PPh3)3]+[Fe4S3(NO)7]− salt (30% probability ellipsoids). Selected interatomic 
distances [pm] and angles [º]: Fe(1)-Fe(2) 258.8(2), Fe(1)-Fe(3) 260.6(2), Fe(1)-Fe(4) 258.7(2), Fe(2)-Fe(3) 
260.6(2), Fe(2)-Fe(4) 262.2(2), Fe(3)-Fe(4) 259.0(2), Fe(1)-S 224.0(9), Feb-S 220.6(9), Fe-P 228.0(6), S-Fe(1)-S 
103(2), S-Fe(1)-N(1) 113.6(3), Fe(1)-S-Feb 71.4(4), Feb-S-Feb 72.4(7), S-Feb-S 107.4(9), S-Feb-N 125.4(17), S-Feb-
P 92.3(4), N-Feb-P 98(3). Data involving P, S, and N atoms are mean values under idealized trigonal symmetry (Feb 
= Fe(2)-Fe(4)). Phenyl group orientations in this cluster and [Fe4S3(NO)4(PPh3)3] are similar. The structure of 
[Fe4S3(NO)4(PPh3)3]+ in this compound as in the PF6−  salt are essentially identical.  (Reprinted with permission from 
Angew. Chem. Int. Ed. Engl., 1993, 32, 564-566.  Copyright 1993 John Wiley & Sons, Inc.)   
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 Figure 2.60 presents the reactions through which the phosphine-ligated cuboidal clusters 
were formed.  Reaction 1 involves reductive desulfurization of the cubane core of [Fe4S4(NO)4] 
accompanied by binding of phosphine.  In reaction 2 PPh3 is replaced by a more basic phosphine.   
 
 
 
 
 
 
Figure 2.60 − Synthesis of [Fe4S3(NO)4(PR3)3]0,1 (R = Ph, Et, Pri, Cy) 
Synthesis of cuboidal clusters [Fe4S3(NO)4(PR3)3]0,1 (R = Ph, Et, Pri, Cy) (Reprinted from Inorg. Chim. Acta, 270, 
Synthesis and structures of the cuboidal iron-sulfur-phosphine clusters [Fe4S3(NO)4(PR3)3]0,1 (R = Et, Pri, C6H11”, 
46-54, Copyright 1998, with permission form Elsevier 146). 
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 Geiser and Williams prepared the analogous bis(tetra-n-butylammonium) hexa-μ3-
sulfido-hexakis(nitrosoiron), (TBA)2[Fe6S6(NO)6], shown in figure 2.61,  by substituting tetra-n-
butyl ammonium hydroxide for ammonium hydroxide in synthesis of Roussin’s salt.151  The 
crystal structure shown in Figure 2.62 reveals that the (TBA)2[Fe6S6(NO)6] complex is composed 
of two fused rings bearing terminal Fe bound nitrosyl groups. Bond lengths and angles are 
consistent  with those reported by Scott and Holm149. 
 
Figure 2.61 − [N(C4H9)4]2[Fe6S6(NO)6] 
Bis(tetra-n-butylammonium) Hexa-μ3-sulfido-hexakis(nitrosoiron). (Reprinted from Acta Cryst., C54, Urs Geiser 
and Jack M. Williams, “Bis(tetra-n-butylammonium) Hexa-μ3-sulfido-hexakis(nitrosoiron)”, 292-293, Copyright 
1998 with permission from the International Union of Crystallography). 
 
Figure 2.62 − The Anion in (TBA)2[Fe6S6(NO)6] 
Shown with the anion in (TBA)2[Fe6S6(NO)6] and with atomic labels.  Selected inversion-symmetry-generated Fe 
atoms are indicated with a suffix A in the atomic label.  The atomic displacement ellipsoids are drawn at the 50% 
probability level.  Short Fe---Fe contacts of ca 2.6 Å are drawn as dashed lines.  (Reprinted from Acta Cryst., C54, 
Urs Geiser and Jack M. Williams, “Bis(tetra-n-butylammonium) Hexa-μ3-sulfido-hexakis(nitrosoiron)”, 292-293, 
Copyright 1998 with permission from the International Union of Crystallography). 
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 Longoni and co-workers completed electrochemical and chemical investigations of the 
redox behavior of  the black Roussinate [Fe4(μ3-S)3(NO)7]− monoanion.144 They have compared 
the two forms of the redox couple [Fe4(μ3-S)3(NO)7]− / 2 − as their tetraethylammonium salts 
(Figure 2.63), and made the spectroscopic assignments for the [Fe4(μ3-S)3(NO)7]- / 2 – / 3- series of 
compounds.   Extended Huckel molecular orbital calculations revealed a doubly degenerate 
LUMO;  the two orbitals, which are antibonding with respect to the Fe-Fe, Fe-S, and Fe-NO 
interactions,  are derived mainly from the four iron atoms and either one of the remaining 
nitrosyl ligands.  Structural evidence supports the theoretical conclusions.   
 
 
 
Figure 2.63 − ORTEP Drawing of [Fe4(μ3-S)3(NO)7]− Monoanion 
Also representative of that of the corresponding [Fe4(μ3-S)(NO)7]2− (Reprinted with permission from Inorg. Chem., 
1993, 32, 1153-1160. Copyright 1993 American Chemical Society.141 ) 
 
 
Curtis and co-workers152 synthesized a series of heterobimetallic iron sulfido nitrosyl 
clusters via the reactions shown in Figure 2.64  In the first reaction, two equivalents of 
Na[Fe(CO)3NO] along  with [CpEt2Mo2S4]2+  (CpEt = C5Me4Et) in THF yield 
81 
 CpEt2Mo2Fe2S4(NO)2; in the second and third reactions, CpEt2Mo2S4 and Cp2Mo2(S)2(μ-SH)2 
react with Fe(NO)2(CO)2 at reflux in toluene to produce the CpEt2Mo2Fe2S4(NO)2 and 
Cp2Mo2Fe2S4(NO)2 clusters, respectively.  Another substrate, Cp*2W2S4, was used to prepare the  
tungsten Cp* analogue of the complexes shown in Scheme 2.64.  Cp*2W2S4  reacted with 2.5 
equivalents of Fe(NO)2(CO)2  at reflux in toluene for two hours to yield Cp*2W2Fe2S4(NO)2 
(Figure 2.65). Crystal structures for CpEt2Mo2Fe2S4(NO)2 and for  Cp*2W2Fe2S4(NO)2 can be 
seen in Figures 2.66 and 2.67.   
 
Figure 2.64 − Synthesis of Sulfido Nitrosyl Clusters 
(Reprinted with permission from Organometallics, 1997, 16,  275-284. Copyright 1997 American Chemical Society 
148). 
 
 
 
 
 
 
Figure 2.65 − Synthesis of the Cp* Analogue 
(Reprinted with permission form Organometallics, 1997, 16, 275-284. Copyright 1997, American Chemical Society. 
148). 
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igure 2.66 − ORTEP Plot
hown with the atomic numbering scheme.  Thermal ellipsoids are drawn at the 50% probability level. (Reprinted 
-284. Copyright 1997, American Chemical Society 148
 
 
 
 
F
S
 of CpEt2MoFe2S4(NO)2
with permission form Organometallics, 1997, 16, 275 ). 
 
gure 2.67 − ORTEP Plot of Cp*2W2Fe2S4(NO)2
hown with the atomic numbering scheme.  Thermal ellipsoids are drawn at the 50% probability level. (Reprinted 
5-284. Copyright 1997, American Chemical Society 148
 
 
 
 
Fi
S
with permission form Organometallics, 1997, 16, 27 ). 
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 Core geometries are consistent with theoretical bonding schemes for clusters that follow 
the 18 electron rule.  Electrochemical analysis reveals multiple stable oxidation states and lower 
energy HOMOs for these nitrosyl complexes in comparison to isostructural carbonyl complexes.  
This is consistent with better stabilization of the π electrons by NO+ than CO. 
Rossell and Seco et al.153 were interested in using nitrosyl containing clusters as 
precursors to nitrido clusters via hydrogenation, electrophilic attack and deoxygenation. The 
ruthenium analogue of the target complex, [Ru C{AuPPh }(CO) (NO)]154 had been synthesized 
by reacting [Ru6C(CO)15(NO)]− with ClAuPPh3. This method was unsuccessful with 
[Fe C(CO) (NO)] − due to the poor nucleophilicity of the iron derivative in comparison to that of 
the ruthenium derivative.  Another route, which involved the reaction between (NEt4)[Fe6C{μ3-
AuPPh3}(CO)16] with NOBF4, yielded [Fe6C{AuPPh3}(CO)15(NO)];  the same reaction with 
excess NOBF4 produced [Fe4C{AuPPh3}(CO)11(NO)].  [Fe4C{AuPPh3}(CO)11(NO)] was 
characterized by X-ray crystallography and elemental analysis.  Among eleven linear CO groups, 
the NO group could not be identified conclusively from the X-ray crystal data; however, other 
experimental evidence indirectly confirms its presence. 
Pergola,  Manassero, and co-workers155 reported an unusual reaction between 
[Fe4N(CO)12]- and Mo(CO)3(EtCN)3 which produces the [Fe6N(CO)15]3- and a small amount of 
the nitrido-nitrosyl iron cluster [Fe N(CO) NO]2- depicted in figure 2.68. The interstitial nitride 
is surrounded by the six iron atoms which define an octahedron.  The linear nitrosyl group has an 
Fe-N-O angle of 176.4(3)° an Fe-N bond distance of 1.677(3) A, and absorbs in the infrared 
region at 1723 cm-1.  While it is clear that the NO ligand forms from oxidation of the exposed 
nitride, the oxygen source is uncertain.  The authors propose that thermal activation of a carbonyl 
or molybdenum mediated splitting of a carbonyl may provide the oxygen.  
6 3 15
6 15
6 14
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Figure 2.68 − The Solid State Structure of [Fe6N(CO)14NO]2-
Carbon atoms are labeled as the oxygen to which they are attached.  Relevant bond lengths and angles:  Fe(1)-N(1) 
1.677(3) Å, N(1)-O(1) 1.175(4) Å; Fe(1)-N((1)-O(1) 176.4(3)º.  (J. Chem. Soc. Dalton Trans., 2001, 2179-2183 - 
Reproduced by permission of The Royal Society of Chemistry. 151) 
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 2.7. NON-HEME NITROSYL COMPLEXES 
Many metalloproteins including deoxyhemerythrin,154 ribonucleotide reductase,156 and  
isopenicillin N synthase,157 possess non-heme ferrous centers which  reversibly bind NO to form 
EPR active S = 3/2 {FeNO}7 centers.  Two complexes, [Fe(EDTA)(NO)] and 
Fe[Me3TACN](NO)(N3)2] (Me3TACN = N, N′, N′′-trimethyl-1,4,7-triazacylcononane) are  
classic models of these complexes.158-160 Wieghardt and co-workers158  characterized the 
following octahedral nitrosyl iron complexes by UV-vis, EPR and Mossbauer spectroscopies: 
trans-[(cyclam)Fe(NO)Cl])ClO4 ({FeNO}7,  (S = ½)), cis-[(cyclam)Fe(NO)I]I ({FeNO}7,  (S = 
3/2)), trans-[(cyclam)Fe(NO)Cl]2+ ({FeNO}6,  (S = 0)), and trans-[(cyclam)Fe(NO)I]0 
({FeNO}8,  (S = 0)) where cyclam = 1,4,8,11 – tetraazacyclotetradecane.   
Aminocarboxylates have also been investigated for  potential use as an NO scavengers in 
sepsis.161-163  Ward and Shepherd164 studied the interaction of  NiII, CuII, ZnII and FeII complexes 
of N,N´-bis(pyridylmethyl)ethylenediamine-N,N-diacetate (edampda2-) with NO. See Figure 
2.69 for the structure of edampa2−.  [FeII edampda2−], shown in Figure 2.70, readily and 
reversibly binds NO with a formation constant Kf(NO) = 1.3 × 104 M−1.    Its lack of charge and 
its greater resistance to oxidation compared to [FeII(edta)]2− make [FeII(edampda2−)] a promising 
antisepsis agent and suggest that it may also be a better scavenger than [FeII(edta)]2− in some 
industrial applications. The edampda2- ligand accommodates a variety of coordination 
geometries as demanded by the dn configuration as well.   
  In addition to their biological applications,  FeII aminocarboxylate complexes are 
involved in a key step in the reduction of NO in denitrification processes in aqueous 
solution.165,166 Aminocarboxylato complexes, such as [FeII(edta)(H2O)]166-169 are known for their 
propensity to bind rapidly and readily to NO.170,171   
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Figure 2.69 − N,N´- bis(pyridylmethyl)ethylenediamine - N,N´- diacetate (edampda2-) 
(Reprinted from Inorg. Chim. Acta, 286, Matthew S. Ward, Rex E. Shepherd*, “A reversible NO Complex of 
[FeII(edampda)] and the NiII(edampda) analogue (edampda2- = N, N´- bis(pyridylmethyl) ethylenediamine – N, N´ - 
diacetate)” 197-206, Copyright 1999, with  permission from Elsevier. 160)   
 
 
 
 
 
Figure 2.70 –  [FeII(edampda2-)] 
(Reprinted from Inorg. Chim. Acta, 286, Matthew S. Ward, Rex E. Shepherd*, “A reversible NO Complex of 
[FeII(edampda)] and the NiII(edampda) analogue (edampda2- = N, N´- bis(pyridylmethyl) ethylenediamine – N, N´ - 
diacetate)” 197-206, Copyright 1999, with  permission from Elsevier. 160) 
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 Since aminocarboxylates are inexpensive, they are used in industry to remove NO from 
exhaust gases.61,165,171   Consequently several studies have focused on NO  binding to chelate 
complexes of FeII.164,167  EDTA complexes are the most well studied because they offer many 
possibilities for variation.   Detailed kinetic and thermodynamic data170-174 as well as spectral 
data62,159,170,171,175,176  are available for [FeII(EDTA)(H2O)]2−  complexes. For example Stochel 
and van Eldik et al.177,178 have used  ATR-IR,171 UV-vis spectroscopy and other techniques to 
study the factors influencing the efficiency and reversibility of the NO binding process for the 
EDTA derivatives and other chelates shown in Figures 2.71, 2.72, 2.73, and 2.74.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.71 – EDTA Derivatives 
(Reprinted with permission from Eur. J. Inorg. Chem. 2001, 491-501. Copyright 2001, John Wiley & Sons 174). 
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  Methyliminodiacetic acid (MIDA) derivatives (Figure 2.72) were studied to determine the effect 
of reducing chelate size on NO binding. The MIDA methyl group was replaced by a non-
coordinating group, a coordinating group or a heteroatom.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.72 − MIDA Derivatives 
(Reprinted with permission from Eur. J. Inorg. Chem., 2001, 491-501. Copyright 2001, John Wiley & Sons 174). 
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 The third main group of multidentate ligands, unrelated to EDTA and MIDA, is shown in 
Figure 2.73.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.73 − Non - EDTA Chelating Ligands 
(Reprinted with permission from Eur. J. Inorg. Chem., 2001, 491-501. Copyright 2001, John Wiley & Sons 174). 
 
 
Stronger coordination was observed for chelate ligands bearing donor groups.  Donor 
groups also accelerated oxidation of FeII to FeIII by dioxygen as a result of their tendency to 
transfer electron density from iron to substrates such as dioxygen and nitric oxide.  Finally, the 
binding constant for NO was found to increase as the inductive effect of the chelate increased. 
Oxygen sensitivity correlated with the decreasing ability of the FeII(L)NO complex to release 
NO and with the tendency of the FeII(L)NO to exist in solution as FeIII(L)NO− before 
decomposing to FeIII(L) and N2O.  Van Eldik and co-workers continued their work with 
mechanistic studies of selected FeII complexes with the ligands shown in Figure 2.74.  
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Figure 2.74 − Other Chelating Ligands 
(Reprinted with permission from Eur. J. Inorg. Chem. 2001,  2317-2325. Copyright 2001, John Wiley & Sons. 173) 
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 The FeIImida complex was insensitive to oxygen, had a low binding affinity for NO and 
almost completely released NO under inert gas.  FeIIedta is very oxygen sensitive, had a high 
binding affinity for NO and released NO slowly and incompletely under inert gas. The oxygen 
sensitivity of the FeII complex suggests that the Fe(L)NO complex is stabilized in the form of   
FeIII(L)(NO−) similar to FeIII(L)O2−, as demonstrated by Solomon et al.159 Complementary 
stopped-flow, temperature jump, flash photolysis, and pulse radiolysis techniques were use to 
complete kinetic studies of the formation and dissociation of Fe(L)NO.  The experimental data, 
combined with a variety of previously available kinetic data, illustrates the strong influence of 
the aminocarboxylato chelates on the rate constant and on the overall equilibrium constant.  
However, there appears to be no clear correlation between the constants and the donor groups or 
the charge on the iron (II) complexes.  The binding of NO must be related to the lability of 
coordinated water to the iron(II) center; however, the dissociation reaction must be influenced by 
whether the metal center is FeII-NO or FeIII-NO− or FeI-NO+, which should be related to the 
donor properties of the chelate.  Since the rate constant of formation is likely to be controlled by 
the lability of coordinated water, the rate constant and activation parameters for solvent exchange 
reactions in the absence of a ligand were studied.61    
The reversible binding of NO with aquated iron salts has been studied since 1906.179-182  
The brown ring test, in which the interaction of aquated Fe2+ with NO is used as a spot test for 
nitrite, is a familiar introductory chemistry lab experiment.  Tarte183 has reviewed studies on the 
decomposition products of the brown ring compounds in acidic, neutral, and alkaline 
solutions.184-188  Early magnetic susceptibility, ESR, IR, Mossbauer, and other techniques led to 
the conclusion that the product of the iron ring test was appropriately considered as 
[FeI(H2O)5(NO+)]2+.189-193  However, more recent evidence from studies on non-heme iron 
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 nitrosyl centers in inorganic complexes11-13,121,159,160 and in proteins154,156,157 along with data from 
EXAFS, XAS, Fe-edge measurements, resonance Raman spectroscopy, EPR, absorption 
spectroscopy, MCD spectroscopy, and applied field Mossbauer studies on a series of 
isostructural complexes containing the {FeNO}6/7/8 unit indicated that the {FeNO}7 unit is best 
described as [FeIII(H2O)5(NO−)]2+.  The UV-vis, IR, Mossbauer and EPR evidence described by 
Stochel and van Eldik178 confirms that the brown ring product is also most appropriately 
formulated as [FeIII(H2O)5(NO−)]2+, not as [FeI(H2O)5(NO+)]2+ as previously believed. Activation 
values suggest that the nitrosylation occurs via a dissociative interchange mechanism in which 
NO acts as a nucleophile to displace coordinated water.  The rate determining step is followed by 
rapid intramolecular charge redistribution to produce the final [FeIII (H2O)(NO−)] 2+. Overall, as 
NO displaces coordinated water, FeII is oxidized to FeIII and NO is reduced to NO−.  Complete 
kinetic data is also reported for the reverse reaction, the release of NO to form [FeII (H2O)6]2+. 
This water “assisted” homolysis reaction involves electron transfer followed by simultaneous 
displacement of NO by water. 
There are relatively few well characterized {FeNO}6 non-heme nitrosyl complexes.158,194  
Of the few {FeNO}6 non-heme nitrosyl complexes that have been studied, a few have thiolates 
in their coordination sphere.194,195  Artaud and co-workers194 prepared the first five coordinate 
{FeNO}6 complex with a mixed carboxamido nitrogen and thiolato sulfur donor set to study as a 
model for nitrile hydratase (NHase), an enzyme which binds NO at an FeIII center N-coordinated 
to two peptide amides and S-coordinated to three cysteines. The model complex is short by one 
RS− donor compared to the enzyme. The crystal structure of the diamagnetic square pyramidal 
Fe III, S = 3/2 complex, depicted in Figure 2.75, reveals a linear NO group. The authors consider 
the Mossbauer data (δ = −0.171 mm s−1) and low νNO of 1780 cm−1 as consistent with (FeIV NO−).  
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 They also acknowledge that (FeIINO+) is a major contributor.  When they prepared a related 
dithiolene Fe(NO)L2 complex with four anionic RS− donors, the analogous nitrosyl had 
properties attributed to (FeIINO+) only. 
 
 
 
Figure 2.75 − X-ray Structure of [Fe(N2S2)NO]−  
Cameron projection of the X-ray structure of the nitrosyl complex 2 without H atom labeling (anionic part). 
Reprinted from Inorg. Chim. Acta, 336, Sandrine Chatel, Anne-Sophie Chauvin, Jean-Pierre Tuchagues, Philippe 
Leduc, Echardt Bill, Jean Claude Chottard, Daniel Masuy, Idabelle Artaud, “Structural and spectroscopic 
characterization of a five coordinate {FeNO}6 complex derived from an iron complex with carboxamido N and 
thiolato S donors,” 19-28, Copyright 2002 with permission from Elsevier 175. 
 
 
Initially, the Enemark−Feltham system, which has been used to predict bent or linear 
nitrosyls, was applied to strong field ligand sets that were available at the time of their work.  
Enemark and Feltham’s rules do not explain cases for bent NO+ arrangements described by 
Hoffman or account for weak field metal nitrosyls.  Current investigation into metal-nitrosyl 
ligand field effects have appeared to fill the void of the Enemark and Feltham assignments.  
Shepherd and co-workers167 studied [FeIIL] and FeIIL(NO) complexes of polyaminocarboxylates 
and pyridylmethylamines as models for {FeNO}7 nitrosylated nonheme proteins  which adopt 
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 the unusual S = 3/2 spin state.  The series of ligands studied, included nitrilotriacetate (nta3-), 
N,N-ethylenediaminediacetate (uedda2−), 2-pyridylmethyliminodiacetate (pida2−), tris(2-
pyridylmethyl)amine (tpa), and N, N, N′, N′-tetrakis(2-pyridylmethyl)ethylenediamine (tpen), 
illustrated in Figure 2.76, was chosen to demonstrate the effects of increasing ligand field 
strength or molecular orbital filling patterns.  The complexes were investigated with differential 
pulse polarography (DPP), cyclic voltammetry (CV), and electron paramagnetic resonance 
spectroscopy (EPR).  Of the [FeIIL] complexes studied, [FeII(uedda)(H2O)2] had the lowest 
effective stability constant and was not studied further.  Formation of the FeIIL(NO) complexes 
of the ligands nta3−, pida2−, and tpa was indicated by the appearance of yellow-green solutions 
upon admission of NO to the respective FeIIL complexes.  Formation of the FeIIL(NO) 
complexes was confirmed by CV and DPP analysis. As depicted in Figure 2.77, EPR 
investigations show that, similar to the [Fe(edta)NO]2− control, which is known to be an S = 3/2 
ground state with resonances  
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igure 2.76 − Polyaminocarboxylate and Pyridylmethylamine Complexes 
, Diane E. Junker, 65, “Ligand field 
 
 
 
 
F
(Reprinted form J. Inorg. Biochem., Rex E. Shepherd*, Michael A. Sweetland
7factors promoting S =  3/2 {FeNO}  nitrosyls”, 1-14, Copyright 1997 with permission from Elsevier. 163) 
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Figure 2.77 − EPR Spectra of [FeL(NO)] Complexes 
At 77 K in 0;01 M frozen NaCl. [FeIIL] ≈ 5.0 x 10-3 M, Ar/NO gas passed for 3-5 min. before freezing in liquid N2:  
(1) [Fe(pida)(H2O)NO], field markers; A, B: g = 4.02 and 2.00:  (2) [Fe(nta)(NO)(H2O)]-, field markers: A, B, C: g 
= 4.36, 4.02, and 2.00: (3) [Fe(edta)NO]2- (control), field markers: A, B, C: g = 4.28, 4.02, and 2.00.  (Reprinted 
form J. Inorg. Biochem., Rex E. Shepherd*, Michael A. Sweetland, Diane E. Junker, 65, “Ligand field factors 
promoting S =  3/2 {FeNO}7 nitrosyls”, 1-14, Copyright 1997 with permission from Elsevier. 163) 
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 at g = 4.1, 3.9, and 2.0, [Fe(nta)NO(H2O)]− and [Fe(pida)(H2O)(NO)] exhibit resonances near g 
= 4.0 and 2.0 which also indicate an S = 3/2 ground state.  A nearly axial EPR spectrum with 
peak and trough features at g = 4.00 and 3.48 indicate a ground state S = 3/2 nitrosyl for 
[Fe(tpa)Cl(NO)]+ as well.  In contrast, EPR studies of [Fe(tpen)NO]2+ reveal signals at g = 2.032, 
1.973, and 1.960.  Since the starting complex, [Fe(tpen)]2+, is known to be six coordinate, NO 
addition must occur either with loss of a pyridyl donor or with expansion of the coordination 
number to seven. Since a seven coordinate pentagonal bipyramidal moiety would reduce ring 
strain for all pyridyl donors, and since no N-shf structure appears in the EPR spectrum, 
coordination most likey occurs with the expansion of coordination number.  EPR and 
electrochemical data suggest a HOMO with an almost purely metal centered character.   
The EPR and electrochemical results, and the fact that CO fails to coordinate to [FeII(nta)], 
[FeII(pida)] and [FeII(tpa) fragments are explained by the ligand field splitting diagrams of six 
coordinate complexes shown in figure 2.78.  In the absence of a strong ligand field, metal d 
orbitals lie above the ligand based bonding molecular orbitals and below the π*xy levels of NO. 
The approximate C4v symmetry is split into Cs symmetry, which is more correct for asymmetric 
six coordinate complexes. The molecular orbital diagram for free NO and free Fe(II) in D5h 
symmetry, illustrated to the left in Figure 2.78, is ensured by failure of NO to oxidize Fe(II) in 
the absence of coordination. The second molecular orbital diagram in Figure 2.78 shows that the 
(eπ*xy)1 orbitals of the NO ligand split as the FeNO moiety bends upon NO coordination in the 
presence of weak field donors, such as the nitrogen and the oxygen donors of nta3-, pida2-, or tpa 
(Figure 2.76). The ligand based π* orbitals remain at higher energy, albeit close to the energy of 
the d orbitals.  As a result, spin pairing of the 1a′′yz orbital is removed and an electron transfers to 
the NO π* orbital, spin parallel with the original π* electron of free NO.  The presence of 
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 electrons in the 2a′′xz and 1a′′yz with simultaneous filling of the aπ*x(NO), aπ*y(NO) levels requires 
the spin opposed arrangement in order for electrons to share the same region of space since the 
π* based molecular orbitals of NO are spatially overlapping with the ayz and axy orbitals.  
 
 
 
 
 
Figure 2.78 − Six-coordinate Complexes before Jahn-Teller Effects 
Note:  The spacing between MO levels is actually increased in the strong field case, promoting spin pairing.  The 
figure does not mean to imply equal spacing energetically. (Reprinted form J. Inorg. Biochem., Rex E. Shepherd*, 
Michael A. Sweetland, Diane E. Junker, 65, “Ligand field factors promoting S =  3/2 {FeNO}7 nitrosyls”, 1-14, 
Copyright 1997 with permission from Elsevier. 163) 
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 Solomon196 had previously presented the same argument to explain the similar influence in 
[Fe(edta)NO]2−.  Spin polarization stabilizes the system and produces a net S = 3/2 ground state 
for [Fe(nta)NO]−, [FeII(pida)NO(H2O)] and [FeII(tpa)NO(X)]+  (X = Cl−, CH3CO2−, H2PO4−, 
etc.).  Spin polarization also substantially stabilizes metal ligand bonds when π bonding is poor.  
The existence of a weak field six coordinate {FeNO}7 species, then, is largely due to the 
stabilization conferred by spin polarization.  The weak field molecular orbital diagram for NO 
coordination yields formal electron counting assignments of {FeIII, S = 5/2), NO− (S = 1)}; 
however, the coordination number of six ultimately influences the percentage of NO based 
character.  In contrast with the molecular orbital diagram for the weak ligand field case, in the 
presence of a strong ligand field the energy of the dx2-y2 levels is higher than that of the π* levels 
of NO, a situation that favors π mixing between the dxz orbital and the π*x orbital of NO.  The π*x 
and the π*y orbitals of NO split to give σ based sp2 type orbital and an energetically increased 
2a′(xzsp2N) level.  As a result the strong field order reverts to the one predicted by the 
Enemark−Feltham rules. 
Except for approximate D5h symmetry, characteristic of a pentagonal bipyramid, the 
analysis for seven coordinate complexes is similar to that for six coordinate complexes (pseudo-
C4v symmetry). Column 2 of Figure 2.79 shows the molecular orbitals of seven coordinate weak-
field complexes such as [Fe(edta)NO]2-. The seven coordinate complexes establish spin 
polarization to yield an FeIII (S = 5/2), NO- (S = 1) electronic arrangement with a net spin of 3/2 
in the ground state.  Column  3 in figure 2.79 illustrates the molecular orbital order for seven 
coordinate strong field complexes such as [Fe(tpen)NO]2+.  Stabilization is enhanced by mixing 
the exz,yz with two orbitals of suitable π* symmetry from ligands such as the pyridyl donors of 
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 tpen.  After the appropriate Jahn−Teller distortion, column 4 in figure 2.79 shows that the highest 
energy electron resides in purely metal based orbital parented largely by dxy.  As a consequence, 
the EPR spectral lines should lack shf coupling from the coordinated NO group, as is observed 
experimentally.   Thus, the formal electron assignment for strong field six or seven coordinate 
complexes is best designated as {Fe(I)(S=1/2), NO+ (S =0)} for a net S = ½ ground state for the 
tpen complex. 
 
 
 
 
 
Figure 2.79 − Ligand Field Splitting Diagram for Seven Coordinate Complexes 
(Reprinted form J. Inorg. Biochem., Rex E. Shepherd*, Michael A. Sweetland, Diane E. Junker, 65, “Ligand field 
factors promoting S =  3/2 {FeNO}7 nitrosyls”, 1-14, Copyright 1997 with permission from Elsevier. 163) 
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 In contrast with the highest occupied molecular orbital for seven coordinate {FeNO}7 
complexes, the HOMO for six coordinate {FeNO}7 complexes retain nitrogen-based as well as 
dxz character, as shown in Figure 2.79.  Hence, strong-field six-coordinate {FeNO}7 complexes 
should exhibit shf coupling.  This EPR spectral outcome was observed with the strong field 
macrocyclic 2,3,9,10-tetramethyl-1,4,8,11-tetraazacyclododeca-1,3,8,10-tetraene (TIM) ligand 
(Figure 2.80) which produces low-spin FeII complexes. [Fe(TIM)(CH3CN)(NO)]2+ exhibits N-shf 
coupling from the axial NO group and an S = ½ ground state.  
 
 
 
Figure 2.80 – TIM Ligand 
(Reprinted form J. Inorg. Biochem., Rex E. Shepherd*, Michael A. Sweetland, Diane E. Junker, 65, “Ligand field 
factors promoting S =  3/2 {FeNO}7 nitrosyls”, 1-14, Copyright 1997 with permission from Elsevier. 163) 
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2.8. CONCLUSION 
In conclusion, iron porphyrin nitrosyl complexes, non-heme iron nitrosyl complexes, iron 
nitrosyl cluster complexes, and the other iron nitrosyl complexes discussed in this paper are 
important in many biological processes (Appendix B).  Their importance stems from their role as 
nitric oxide carriers and from the range of structural forms they exhibit.  For example, upon 
coordination with NO, a change in the geometry of an iron heme in guanylate cyclase induces a 
conformational change that opens an active site to guanosine triphosphate. Guanosine 
triphosphate is then converted to cyclic guanosine monophosphate which helps regulate blood 
pressure.  In order to develop iron nitrosyl complexes for medicinal purposes, it is crucial to 
understand the nature, origin and effect of such structural changes. 
Structural features of iron nitrosyl complexes are controlled by several factors.  The 
dominant factors seem to be the number of electrons within the MNO moiety (n in {MNO}n)  
and the coordination number.  Within a given {MNO}n and coordination number system, subtle 
changes of the ligand donors alter the placement of NO π* orbitals relative to the d orbitals 
within a certain geometry.  Population of antibonding orbitals in these systems leads to a bent 
nitrosyl group.     The recent identification of many Fe spin state coupled with NO spin state 
combinations, expands MNO characterization well beyond the standard classifications for linear 
NO+ or bent NO− systems.  For example, deviations from linearity for {MNO}6 systems, have 
been observed. Refinement of early classifications to account for such deviations is made 
possible by the many analytical techniques available today. Together, Cyclic voltammetry, EPR, 
magnetic susceptibility, NMR, and X-ray crystallography, Mossbauer spectroscopy, and UV-vis 
spectroscopy are used to establish and verify the geometry of NO, as well as the oxidation state, 
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 and spin state assignments within the MNO unit.  These techniques provide a more complete 
picture of iron nitrosyl complexes than was ever possible.  The trend toward merging biological 
and chemical knowledge about iron nitrosyl complexes provides a more balanced perspective on 
what mechanisms control the behavior of the various physiologically important iron nitrosyl 
complexes.  All of these factors combine to accelerate advances in iron nitrosyl chemistry and in 
transition metal nitrosyl chemistry. 
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  APPENDIX A 
 
NITRIC OXIDE SYNTHASE 
 
 
Lincoln et al.27 have summarized the evolution of the nomenclature that describes the isoforms 
of nitric oxide synthase. Initially nitric oxide synthases were classified in terms of whether their 
activity was calcium dependent, (cNOS) or calcium independent (iNOS).  At the time it was 
accepted that, in general, cNOS is constitutive (ever present under normal conditions; activation 
doesn’t require new enzyme protein synthesis) while iNOS is inducible (only expressed under 
activation; new enzyme protein synthesis occurs in response to certain stimuli).197  Constitutive 
NOS enzymes are responsible for mediating rapid events such as neurotransmission and blood 
vessel dilation.   For example, within seconds a glutamate induced increase in Ca2+ levels 
activates neuronal NOS via calmodulin;  similarly, the endothelial form of NOS is activated by 
an increase in intracellular Ca2+ which facilitates binding of calmodulin. The increase in 
intracellular Ca2+ is caused by activation of the phosphoiniside cycle by action of acetylcholine 
or bradykinen on endothelial muscarinic or bradykinen receptors.  The function of calmodulin 
will be discussed in more detail later. An example of an inducible NOS is the NOS that is 
induced in macrophages by the presence γ-interferon and lipopolysaccharide to destroy 
tumors.197   
As experimental evidence accumulated, it became apparent that some inducible NOS 
enzymes are also constitutive, and that constitutive NOS enzymes could be induced.197  So 
another classification was developed based upon whether the cells of NOS origin were 
endothelial (eNOS) or neuronal (nNOS). When the three isoforms were finally purified and 
cloned, another designation was required because, while the first isoform  (Type I NOS) is  
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 constitutive and found in neurons in rat and porcine cerebellum, it is also present in skeletal 
muscle, endometrium, and neutrophils, among other tissues and cells.  The second isoform (Type 
II NOS), which is inducible, was cloned from murine macrophages, and is also inducible in cells 
from neurons and from endothelial cells.  The isoform (Type III NOS) that was cloned from 
bovine vascular endothelial cells is also present in neurons.   Since a family of three genes has 
been identified to encode for the three forms of  NOS, Nathan and Xie198 have proposed to 
combine the findings on the NOS genes with an earlier numerical classification to define the 
isoforms in a way that is independent of the cells of origin  or of whether they are inducible or 
constitutive, but that expresses the dependence of their activity on Ca2+.  Their suggested 
nomenclature is shown in Figure A.1.   Another classification is based upon the physiological 
roles played by NO.  These are as follows, inducible NOS (iNOS, immune system), neuronal 
NOS (nNOS) and endothelial NOS (eNOS cardiovascular system).18   
 
Preferred Designation                                                 
                                                                                                                                                                Chromosomal 
Numericala             Descriptive            Definition                                                                                 Localization (Human)   
I                               ncNOS                 NOS whose activity depends on elevated Ca2+,b                                          12q24.2 
                                                                                            of the type first identified in neurons                                  
II                              iNOS                    NOS whose activity is independent of elevated Ca2+,b                            17cen-q12 
III                         ecNOS                  NOS whose activity depends on elevated Ca2+,b,7                          q35-36 
                                                             of the type first identified in endothelial cells 
                                       a Simplified from Schmidt et al (1991). 
                                       b Above the level in resting cells 
  Figure A.1 − NOS Nomenclature  
  (Reproduced from Cell, Carl Nathan and Qioa Wen Xie, “Nitric Oxide Synthases:  Roles, Tolls and Controls”,   
  915- 918, Copyright 1994 with permission from Elsevier. 196) 
 
Once the NOS isoforms were cloned, the structures of the three isoforms were elucidated.  
As shown in Figure A.2,  nitric oxide synthases all seem to include an oxygenase and a reductase 
domain between which the Ca2+ dependent binding protein, calmodulin, resides.26,27,197  The 
reductase domain is homologous with that of cytochrome P450 reductase, which is also shown in 
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 Figure A.2.  Cytochrome P-450 reductase is the only other mammalian enzyme that exhibits 
recognition sites for nicotinamide adenine dinucleotide phosphate, (NADPH) flavin 
mononucleotide  (FMN), and flavin adenine dinucleotide (FAD)197,199 (Figure A.3).  
 
 
 
 
 
 
 
Figure A.2 − NOS Isoforms and NADPH-Cytochrome P450 Reductase 
“Diagram displaying the structural relationship between the NOS isoforms and NADPH-cytochrome P450 reductase 
(CPR).  The cloned NOS isoforms from brain (bNOS), endothelium (eNOS), macrophage (macNOS), and 
hepatocytes (hepNOS) are all comprised of an oxygenase and reductase domain, with a binding domain for 
calmodulin between them.  The reductase domain contains binding sites for NADPH, FAD, and FMN, and is 
homologous with the dual flavin enzyme NADPH-cytochrome p450 reductase.  The oxygenase domain on bNOS 
and eNOS contain phosphorylation sites (P).  Also noted are a myristoylation site near the N terminus of eNOS, a 
hydrophobic transmembrane anchoring domain in CPR.” (Reprinted from Nitric Oxide Principles and Actions, “The 
Intracellular Reactions of Nitric oxide in the Immune System and Its Enzymatic Synthesis”, Jack Lancaster, Jr. and 
Dennis J. Stuehr, p.153, Copyright 1996, with permission from Elsevier.) 
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Figure A.3 − Prosthetic Groups Contained within NOS   
“Prosthetic groups contained within NOS.  Nitric Oxide synthases are isolated containing approximately one 
molecule each of heme, FAD, and FMN per subunit, and also contain variable quantities of tetrahydrobiopterin (0.1 
to 1 molecule per subunit)” (Reprinted from Nitric Oxide Principles and Actions, “The Intracellular Reactions of 
Nitric oxide in the Immune System and Its Enzymatic Synthesis”, Jack Lancaster, Jr. and Dennis J. Stuehr, p.152, 
Copyright 1996, with permission from Elsevier.) 
 
 
The Combination of NADPH, FMN and FAD in NOS suggests that, as in cytochrome 
P450 reductase, the NOS flavins store NADPH derived electrons prior to transferring them to a 
catalytic center in the NOS oxygenase domain. The heme unit and the tetrahydrobiopterin are 
presumed to bind in the oxygenase domain.  A highly conserved 320-amino-acid region exists in 
all NOS oxygenase domains. Modeling studies have shown that within this sequence is a 
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 cysteine residue which may be involved in heme iron ligation.200,201    The heme unit reacts with 
CO to form a species which absorbs at 445 nm.  CO also inhibits purified NOS.  These 
observation also suggest the involvement of a cytochromeP-450 type heme which is coordinated 
to a cysteine ligand.28,200,202,203  However, as Figure A.4 shows, there is no significant homology  
between the cytochrome P-450 and NOS, even at the N-terminus where the heme is located.  See 
figure A.2.  This lack of homology is expected since the P-450’s act on hydrophobic substrates 
while NOS acts on L-arginine which is hydrophilic.  So, while NOS uses the P-450 
chromophore, NOS itself doesn’t fit the category of  P-450 enzyme.204 
 
 
 
 
 
 
 
 
 
 
Figure A.4 − Sequence Homologies of Molecular Isoforms of NOS 
 “Sequence homologies of molecular isoforms of NOS. All NOS enzymes cloned thus far have homologous regions 
to cytochrome P450 reductase and substrate binding sites that reflect the oxidative mechanism of NO biosynthesis.  
Consensus binding sites for FAD, FMN, NADPH, and calmodulin are conserved for all NOS enzymes cloned.  
Protein kinase A phosphorylation sites (labeled P).  Abbreviations: P, consensus sequence for  phosphorylation by 
cAMP-dependent protein kinase; CAL, calmodulin binding site; FMN, flavin mononucleotide; FAD, flavin adenine 
dinucleotide; H, heme binding site; NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; TMD, 
transmembrane domain, M, myristoylation site. (Reprinted with permission from J. Neurosci., 1994, 14, 5147-5159. 
Copyright 1994 Society for Neuroscience. 195) 
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 The peptide that connects the heme and the flavin domains is the peptide that binds 
calmodulin in the presence of Ca2+.  Binding to calmodulin16,22,205 induces a structural change 
that permits electrons to  flow from the flavin to the heme domain Figure A.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.5 − Role for Calmodulin in Control of Heme Reduction in NOS 
“Role for calmodulin in control of heme reduction in NOS. (A) In the absence of bound calmodulin, electrons 
derived from NADPH can load into the flavins but cannot be transferred onto the heme iron. (B) On calmodulin 
binding, electrons transfer from the flavins onto the heme.  In the absence of bound L-arginine, heme reduction 
generates superoxide (C), whereas in the presence of L-arginine, heme reduction can lead to NO synthesis.” 
(Reprinted from Nitric Oxide Principles and Actions, “The Intracellular Reactions of Nitric oxide in the Immune 
System and Its Enzymatic Synthesis”, Jack Lancaster, Jr. and Dennis J. Stuehr, p.161, Copyright 1996, with 
permission from Elsevier.) 
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               In the presence of L-arginine, electron transfer to the heme generates NO.  Calmodulin 
and Ca2+ control the activity of the constitutive NOS forms, so, it was not surprising that 
calmodulin sequences were found in all constitutive isoforms.  It was surprising, however, that 
the inducible forms of NOS also exhibited calmodulin recognition sequences.  The discrepancy 
was resolved when the iNOS derived from murine macrophages was purified with calmodulin 
subnunit bound so tightly that it rendered the NOS virtually insensitive to changes in Ca2+ 
concentration.204,206  This  keeps iNOS in its active state.206 The affinity of that particular iNOS 
for calmodulin is sufficiently high that only negligible amounts of Ca2+ are required for 
activation.  Other inducible isoforms are somewhat inhibited upon exposure to Ca2+chelating 
agents, CaM antagonists, or both.  The propensity of constitutive and inducible isoforms to bind 
calmodulin is depicted in Figure A.6.    
 
Figure A.6 − Calmodulin Binding 
Calmodulin Binding by Constitutive and Inducible NOS Isoforms (Reprinted from Cell 78, Michael Marletta, 
“Nitric Oxide Synthases:  Aspects Concerning Structure and Catalysis, 927-930, Copyright 1994, with permission 
from Elsevier.) 
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 Although the exact role of tetrahydrobiopterin, a redox active cofactor,207-210 is unclear, it 
may facilitate L-arginine binding by stabilizing the enzyme.29,211,212 Whether tetrahydrobiopterin 
is redox active in NOS is not known conclusively.  It is known that tetrahydrobiopterin deficient 
NOS displays a diminished capacity to generate NO via electron flow from NADPH.207,211,213 
Instead of producing NO, the tetrahydrobiopterin deficient NOS transfers electrons from 
NADPH to oxygen to create superoxide.213  So, tetrahydrobiopterin seems to be involved in 
connecting NOS NADPH oxidation with NO synthesis.   Tetrahydrobiopterin also may have a 
catalytic role in NO synthesis.  Brain and macrophage NOS isoforms exist as 
homodimers.202,214,215  A mixture of monomeric and dimeric forms of macrophage NOS has been 
isolated.216 In the monomeric form macrophage NOS has FAD, FMN, and calmodulin  and lacks 
bound heme and tetrahydrobiopterin.  Without heme and tetrahydrobiopterin, the monomeric 
form of macrophage NOS only acts as an NADPH-dependent reductase toward acceptors such as 
cytochrome c or ferricyanide.26,216  This finding strongly suggests that tetrahydrobiopterin 
functions as a reductase. The crystal structure of the heme domain of endothelial NOS in 
tetrahydrobiopterin free and bound forms was obtained Poulos and co-workers;217  their 
conclusions also support the theory that tetrahydrobiopterin acts as an electron transfer agent.   
Reassociation of the monomeric forms to form their active dimeric forms is required for NO 
production. Reassociation of the monomeric forms to form their active dimeric forms requires 
the presence of tetrahydrobiopterin, L-arginine, and  stoichiometric amounts of heme.26,216  L-
arginine, tetrahydrobiopterin and heme appear to cooperatively interact to facilitate dimerization. 
However, the precise mechanism  is unclear.  Figure A.7 illustrates the proposed role played by 
tetrahydrobiopterin in nitric oxide synthesis.26  Regardless of its exact role, tetrahydrobiopterin is 
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 known to be involved in the first step of the reaction sequence that leads to N-hydroxylation and 
ultimately to NO production. 
 
                                             Activated                   Inactive 
 
Figure A.7 − Role for Heme H4biopterin and L-arginine 
“Role for heme H4biopterin, and L-arginine in subunit assembly of macrophage NOS.  Assembly of NOS from its 
isolated subunits in vitro requires that subunits be coincubated with heme, L-arginine and H4biopterin, 
Tetrahydrobiopterin and heme become bound within the dimer during its assembly and enable NOS to catalyze NO 
synthesis.  Dissociation of dimeric NOS leads to loss of its bound heme and H4biopterin, and it generates subunits 
which are inactive regarding NO synthesis.” (Reprinted from Nitric Oxide Principles and Actions, “The Intracellular 
Reactions of Nitric oxide in the Immune System and Its Enzymatic Synthesis”, Jack Lancaster, Jr. and Dennis J. 
Stuehr, p.164, Copyright 1996, with permission from Elsevier.) 
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 APPENDIX B 
 
 
ADDITIONAL BIOLOGICAL ROLES OF IRON NITROSYL COMPLEXES 
 
The more that is understood about the nature of heme and non-heme iron heme nitrosyl 
complexes, the more likely it is that nitric oxide based therapies can be developed to treat 
illnesses at their origin. Thus, much research is devoted to the study of the role of iron heme 
nitrosyl complexes in biology. Iron nitrosyl complexes, whether they are heme, non-heme, 
cluster or bimetallic complexes, are important agents in nitric oxide synthesis and regulation as 
well as in other physiological functions.  This section reviews some of the research directed 
toward the physiological roles of nitric oxide and iron nitrosyl complexes. 
Bastian et al. provided EPR evidence that inducible nitric oxide synthase is activated in 
the cell-mediated immune response to syngenic tumors and that the resulting nitric oxide   
diffuses from cytokine activated macrophages to tumor cells within which it interacts with iron 
containing molecules to form complexes of the general formula [Fe(SR)2(NO)2], as well as five 
and six coordinate heme-nitrsosyl complexes.  Bastian’s study illustrates the existences of iron 
sulfur and iron heme containing nitric oxide targets in murine cancers.33  NOS expressing 
vascular cells can also participate in defense against tumors.218 
   EPR analysis of liver tissue obtained from mice exhibiting chronic inflammation induced 
by infection with Cornybacterium parvum after treatment with lipopolysaccharide revealed a 
cytochrome P420 nitrosyl complex as well as  non-heme nitrosyl complexes.219,220  Detection of 
nitrosylated heme and nonheme iron containing proteins during rejection of rat heart allograft 
(by EPR measurements) suggest that destruction of iron-containing protein function is crucial in 
the rejection response.34 
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 In 1969 it was reported that aquacobalamin does not bind NO.38 However, recent 
evidence suggests that aquacobalamin does bind NO.39-45 Van Eldik and co-workers investigated 
the discrepancy and demonstrated that cobalamin, vitamin B12, doesn’t bind with NO but with 
nitrite impurities in aqueous solution.46 (A side implication of this finding is that, because NO in 
aqueous solutions readily reacts with dissolved oxygen to form other nitrogen oxide species, 
great care must be taken when running experiments with NO in water.46,221) It was shown, 
however, that the reduced form of cobalamin, which is present under physiological conditions35-
37 does react with nitric oxide to form a CoII-NO complex.222  The binding of NO to reduced 
cobalamin may be responsible for the inactivation of some cobalamin-dependent enzymes as 
well as inhibition of NO actions in vivo.  Van  Eldik and co-workers completed a kinetic and 
mechanistic study of the binding of NO to reduced cobalamin.223  The reactivity of nitrite ions 
with reduced cobalamin was also studied.  Spectroscopic and laser flash photolysis results 
support a proposed dissociative interchange mechanism.  Reduced cobalamin reacts with nitrite 
impurities several much more slowly than with NO therefore, the kinetic results were unaffected 
by the presence of nitrite impurities. The authors have also completed a similar study on the 
reaction of NO with metmyglobin.47  Metmyoglobin reacts with NO in a manner analogous to 
that of water-soluble FeIII porphyrin model systems.224  Kinetic studies support a dissociative 
mechanism. 
The X-ray crystal structure of the nitric oxide of the ferrous nitric oxide form of native 
sperm whale myoglobin exhibits a bent nitrosyl.225  Just as nitric oxide binds to metmyoglobin 
and met hemoglobin, so does nitrite.  Binding proceeds by a dissociative mechanism.  Nitrite 
binding is much slower than NO binding therefore kinetic studies of NO binding to 
metmyoglobin and methemoglobin are also unaffected by trace nitrite impurities.226 
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 Hendrich and co-workers carried out Mossbauer and EPR studies of the NO adduct of 
hydroxylamine oxidoreductase.227  Hydroxylamine oxidoreductase, derived from the autotrophic 
nitrifying bacterium, Nitrosomonas europaea, contains eight hemes per subunit. These hemes are 
active in catalysis of the  oxidation of hydroxylamine to nitrite and in electron transport.  
 Mechanistic studies of the reductive nitrosylation of ferricytochrome (CytIII), 
metmyoglobin (MbIII), and methemoglobin (HbIII) reveal that after the initial formation of the 
nitrosyl ferrihemeprotein adduct, the rate limiting nucleophilic attack by OH- to produces the 
ferrohemeproteins plus nitrite.  Rate constants kOH are in the order HbIII  >  CytIII  > MbIII.228 
Kagan48,49 and coworkers demonstrated that nitrosylation of hemoglobin-heme and of 
non-heme iron centers formed complexes that interact with t-BuOOH to prevent cytotoxicity.    
Nitric oxide is proposed to protect cells against oxidative damage by decreasing catalytic heme- 
and non-heme iron sites and by direct chemical interaction with hydrogen peroxide induced free 
radicals such as oxyferryl and alkoxy radicals.  The first pathway may operate after long term 
cell exposure to NO.  The second pathway is a faster reaction that responds to acute and intense 
oxidative stress.  Several investigations suggest that NO acts as an antioxidant by directly 
scavenging radicals or by binding to and hindering metal centers that participate in Fenton-type 
catalysis in oxidation.50-52  Another possible interpretation is that, in addition to reducing 
oxoferryl to ferri-hemoproteins, NO directly quenches t-BuOOH derived radicals, and protein 
radicals.229   
Nitric oxide binds to deoxyhemerythrin which is a derivative of the oxygen transporting 
non-heme protein found in marine invertebrates.17,230  Nitric oxide adducts have been proposed 
as  analogues of a semi-methemerythrin superoxide intermediate in oxygenation.159,231,232  
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 Rodriguez and co-workers completed Mossbauer spectroscopic studies and density functional 
theory investigations of the nitrosyl derivatives of deoxyhemerythrin.154 
 As a radical, nitric oxide has a high affinity toward ferric and ferrous proteins. But, as 
NO+, nitric oxide forms S-nitrosothiols. Reichenbach and co-workers demonstrated that it is 
possible to obtain nitrosothiols from metmyoglobin under physiological pH conditions.53  
Nitrosothiols are important because they are vasodilators, because they inhibit platelet 
aggregation, and are associated with signal transduction.233-235  Albumin, hemoglobin, and 
glyceraldehyde-3-phosphate dehydrogenase are all examples S-nitrosylated proteins.  It had been 
assumed that NO diffused passively into smooth muscle tissue and reacted with proteins that 
cause vasodilation and increased blood flow.  However, given nitric oxide’s high affinity for 
ferro and ferric proteins, hemoglobin in particular, random diffusion is insufficient to explain 
how NO reaches blood vessels.  Blood would immediately consume the nitric oxide.  Pawloski 
and co-workers demonstrated that NO movement is more complicated than simple diffusion.  
They propose that much of the previously considered irreversibly hemoglobin consumed NO 
actually returns to the blood vessel wall as an S-nitrosothiol molecule.  Thus the NO is protected 
from reaction with hemoglobin by a thiol.  Some of the NO bound by Fe2+ hemoglobin is 
transferred intramolecularly to a conserved thiol group to produce S-nitroso-hemoglobin.  The 
authors propose that the nitrosothiol might then transfer the NO group to other thiol containing 
molecules, which carry the NO from the hemoglobin.  This process would be most likely to 
occur in oxygen depleted tissues.  Hemoglobin changes conformation upon loss of oxygen from 
the R (relaxed form) to the deoxygenated T (tense) structure.  This system provides an NO 
delivery system to oxygen poor tissues.  Increased NO concentration causes vasodilation and 
increased blood flow which allows the needed influx of oxygen.  Pawloski and co-workers 
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 suggest that the anion exchange protein AE1 which anchors a subpopulation of hemoglobin 
molecules to red blood cell membranes, may have evolved specifically for the transfer of NO 
groups.233,234  
It is noteworthy that glutathione (GSH) will react with nitric oxide in the presence of 
ferrimyoglobin at physiological pH to form nitrosoglutathione.53  S-nitrosoglutathione also forms 
in vivo from alkylnitrites catalyzed by glutathione transferase.236  So, alkyl nitrites act as 
nitrosating agents in vivo.237  Ethyl nitrite formed upon intake of ethanol may be absorbed by the 
stomach and transported to the duodenum and small intestine.238 
 Given the importance S-nitrosothiols in particular and of nitrosyl complexes in general, 
Loscalzo and co-workers have developed a method of detecting biologically important S-
nitrosothiols and other nitric oxide derivatives using photolysis-chemiluminescence 
spectrometry.239  Photolysis homolytically cleaves the NO radical from its parent compound.  
The NO radical is transported by helium to an ozone chamber in which it is oxidized to the 
electronically excited NO2* which exhibits chemiluminescence upon decay to the ground state.  
Cold traps collect all nonvolatile parent compounds and derivatives.  Although this method, by 
itself, cannot distinguish between different  S-nitrosothiols or other NO derivatives, when used in 
conjunction with HPLC or other separation systems, characterization is possible.   
Gas phase NO has been detected in exhaled breath of animals and humans.  Asthmatic 
patients exhibit increased exhaled NO levels240-244 while cystic fibrosis patients have been 
reported to exhibit decreased exhaled NO levels 244-246 as well as unchanged NO levels as 
compared to healthy subjects.242,243,247-251 Denitrifying bacteria consume nitrogen oxides via 
assimilatory and dissimilatory pathways.  For example, Psuedomonas aeruginosa carries nitric 
oxide reductase which consumes NO and produces NH4+.  Denitrifying bacteria may be 
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 responsible for disrupting nitrogen balance in the airway of cystic fibrosis patients.252  Therefore, 
there is a potential clinical role for the measurement of exhaled NO as a noninvasive 
biological247 marker in the study and treatment of disease.  Previous methods depended on the 
use of anaesthetized mechanically ventilated animals for NO measurement.  However, the effects 
of the anesthetic on NO measurements were unclear.  Mehta and co-workers developed a 
noninvasive method for measuring exhaled NO in a spontaneously breathing mouse.253 
In the respiratory system NOS is found in airway epithelial cells, vascular endothelial 
cells, macrophages, neutrophils, fibroblasts, and neuronal synapses.  Since NOS from any of 
these cells can contribute to exhaled NO, lower respiratory tract NO can come from bronchial or 
alveolar sources.  Patients with liver cirrhosis and with asthma exhibit an increased output of 
exhaled NO.  Multiple flow rate analysis allows the increase NO from a bronchial source to be 
differentiated from that from an alveolar source.254 While cirrhosis of the liver causes an increase 
in NO output from alveolar sources and can participate in arterial hypoxemia, asthma causes an 
increase in NO output from the bronchial tree.  That alveolar NO production in liver cirrhosis 
increases suggests that either there is a local increase in alveolar NO production along with an 
impairment of diffusion through the alveolar capillary wall, or that there is increased NO 
excretion from pulmonary circulation into the alveolar region.  New anesthetic independent 
methods for measuring exhaled NO are being developed.  
Cluster compounds are important in biology.  For example, nitrogenase catalyzes the 
reduction of N2 to ammonia.  Nitrogenase from Azobacter vinelandii has two protein 
components, a homodimeric iron protein and a molybdenum iron protein. The homodimeric iron 
component has one ferredoxin-like center that acts as a bridge between it and the molybdenum-
iron component.  The iron protein catalytically transfers an electron from reduced carriers to the 
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 molybdenum-iron component. The metals in this component are found in chemically distinct 
clusters.  Understanding the role of these clusters is important for elucidating the enzymology of 
Azobacter vinelandii nitrogenase.  Mortenson and co-workers carried out kinetic and 
spectroscopic studies of the inactivating effects of nitric oxide on the two components of 
Azobacter vinelandii.31 
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